

06-17-05

PATENT
674509-2027

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): BOJSEN et al.
Application Serial No.: 10/779,427, which is a divisional of 09/856,819, which is the National Stage of PCT/DK99/00664 and/or any U.S. application that claims priority or continuing status from USSN 09/856,819, USSN 10/779,427 and/or PCT/DK99/00664
For: LIPOLYTIC ENZYME VARIANTS
Filed: November 22, 2004
Examiner: Nashaat T. Nashed
Group Art Unit: 1652

RECEIVED

JUN '22 2005

TECH CENTER 1600/2900


745 Fifth Avenue, New York, New York 10151


EXPRESS MAIL

Mailing Label Number: EV 723367772 US

Date of Deposit: June 15, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450


(Typed or printed name of person mailing paper or fee)


(Signature of person mailing paper or fee)


9/12/05
**WILLIAM R. DIXON, JR.
SPECIAL PROGRAM EXAMINER**

**PROTEST AND/OR PAPER CALLING ATTENTION TO
APPLICATION OF ANOTHER AND
REQUESTING SUSPENSION OF PROSECUTION AND INTERFERENCE**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INTRODUCTION

IDENTITY OF PROTESTORS; STATEMENT OF RELIEF REQUESTED

The plaintiffs in the attachment hereto – a Complaint by Danisco A/S and Jørn Borch SØE against Novo Nordisk and Novozymes that was filed in the U.S. District Court for the

Southern District of New York in Civil Action No. 01-CV-10557 (LTS)¹ – through their attorneys who have an address of FROMMER LAWRENCE & HAUG LLP, 745 Fifth Avenue, New York, NY 10151, hereby Protest any issuance of the above-captioned applications and respectfully request suspension of prosecution in those applications until final adjudication of the issues in the judicial action of the attachment hereto, and declaration of an interference thereafter.

SERVICE ON APPLICANT

A true copy of this paper was served by Express Mail on Jason I. Garbell, Reg. No. 44,116, Novozymes North America, Inc., 500 Fifth Avenue, Suite 1600, New York, NY 10110, attorneys for Applicants.

THE DOCUMENTS UPON WHICH THE PROTEST IS BASED

This Protest is based upon the following documents:

1. The Complaint attached hereto.
2. Co-pending application Serial No. 09/727,852 of Jørn Borch SØE which is believed to claim dominating subject matter as to USSN 10/779,427, and which can be amended to include claims that interfere with the above-captioned applications, as may be suggested by the Examiner, since USSN 09/727,853 incorporates by reference PCT/DK99/00664. Further, the claims of USSN 10/779,427 are believed to NOT be patentably distinct from any interfering subject matter of USSN 09/727,852 and either PCT/DK99/00664 or USSN 09/856,819.

A concise statement of the relevance of the documents cited herein is: that the documents cited herein show that an issue as to the inventorship on the above-captioned applications is pending before a Court, and that a third party, Jørn Borch SØE, has a pending application that is believed to be interfering, and that there may be confidential information available as prior art against the above-captioned applications. Thus, prosecution of USSN 10/779,427 should be suspended for the duration of the Court proceedings and through any subsequent interference, as there are pending issues of inventorship and priority.

¹ Currently on the Court's Suspend Calendar in view of an Arbitration Proceeding between Danisco A/S and Novozymes A/S in Denmark.

BASES FOR PROTEST - EXPLANATION OF RELEVANCE OF CITED DOCUMENTS

From information received from the face of Patent Application Publication 2005/0059130, it is believed that U.S. application Serial No. 10/779,427 is a divisional of U.S. application Serial No. 09/856,819, which is the national stage of PCT/DK99/00664.

As shown by the attachment hereto, there is a judicial action involving inventorship in PCT/DK99/00664 and U.S. application Serial No. 09/856,819 and/or any U.S. application that claims priority or continuing status from or is the national stage of PCT/DK99/00664, published as WO 00/32758. Thus, during the pendency of the judicial action, until final adjudication of the issues therein, it is believed proper that prosecution of the above-captioned applications, e.g., U.S. application Serial No. 10/779,427 and/or any U.S. application that claims priority or continuing status from U.S. application Serial No. 09/856,819 or PCT/DK99/00664 or is the national stage of PCT/DK99/00664, published as WO 00/32758 be suspended; and such action is respectfully requested. Indeed, it is believed that prosecution of the parent application, U.S. application Serial No. 09/856,819 has been suspended on the same basis as herein asserted, on papers previously filed by the herein protestors.

Furthermore, an interference between the above-captioned applications and USSN 09/727,852, advantageously after final adjudication of the issues in the judicial action, is also believed proper and is respectfully requested.

More specifically, Applicant Jørn Borch SØE in USSN 09/727,852, has claimed priority or a continuing status under 35 U.S.C. § 120 from PCT/DK99/00664 (published as WO 00/32758); also, USSN 09/727,852 incorporates by reference PCT/DK99/00664 (published as WO 00/32758). Further still, USSN 09/727,852 contains claims substantially copied from PCT/DK99/00664 (published as WO 00/32758).

Accordingly, it is believed that the above-captioned applications, e.g., USSNs 10/779,427 and 09/856,819 and SØE's application USSN 09/727,852 interfere or can be amended to contain interfering claims, such that a declaration of interference is believed proper, and is hereby respectfully requested.

However, as shown by the attachment hereto, PCT/DK99/00664 presently does not name Jørn Borch SØE, and he and his assignee are pursuing a judicial action to have him so named as an inventor on PCT/DK99/00664, so that his claim of priority or continuing status in USSN 09/727,852 may be perfected. When so named as an inventor on PCT/DK/00664 he shall then

be named as an inventor on USSNs 09/856,819 and 10/779,427 and the PTO is urged to *sua sponte* add him as an inventor on those applications, e.g., by this paper serving as a petition therefor.

Accordingly, while a declaration of an interference between USSN 09/727,852 and the above-captioned applications is respectfully requested, it is also respectfully requested that prior thereto that the prosecution of U.S. application Serial No. 10/779,427 and/or any U.S. application that claims priority or continuing status from U.S. application Serial No. 09/856,819 or PCT/DK99/00664 or is the national stage of PCT/DK99/00664, published as WO 00/32758, be suspended during the pendency of the judicial action, until final adjudication of the issues therein, as those issues materially impact on such an interference and the declaration thereof.

Simply, it is respectfully submitted that the issue of inventorship is critical to, and must be decided prior to, any interference.

Relief requested in the judicial action – that Jørn Borch SØE should be added as a named inventor on PCT/DK99/00664, published as WO 00/32758 and U.S. application Serial Nos. 09/856,819 and 10/779,427 and/or any U.S. application that claims priority or continuing status from or is the national stage of PCT/DK99/00664, published as WO 00/32758 - it is submitted, will allow Jørn Borch SØE to perfect his claim under 35 U.S.C. §120 of continuing status from PCT/DK99/00664, published as WO 00/32758, in USSN 09/727,852.

Once Jørn Borch SØE has so perfected his claim of continuing status, it is believed that in the herein requested interference, neither party will be either Senior party or Junior party. That is, it is believed that the interfering subject matter was first in PCT/DK99/00664, published as WO 00/32758 (and that Jørn Borch SØE is an inventor of that subject matter).

In an interference, the burden of proof on a party is based on his status as either Junior party or Senior party. If neither party in an interference is the Junior party or Senior party, then, it is believed that the parties will have the same burden of proof.

Accordingly, if the issues in the judicial action are not permitted to be adjudicated prior to the herein requested interference, i.e., if there is declaration of the herein requested interference prior to final adjudication of the issues in the judicial action, Jørn Borch SØE could be Junior Party in that interference (because his claim of continuing status to PCT/DK99/00664, published as WO 00/32758 will not have been perfected because he will not have been named as an inventor thereon as the Defendants will not have been Ordered to name him as an inventor

thereon, such that only the Defendants will enjoy the filing date of PCT/DK99/00664, published as WO 00/32758 in the interference). And therefore, Jørn Borch SØE will bear an undue burden of proof in the herein requested interference if it is declared prior to the resolution of the judicial action.

More in particular, to determine the filing dates to accord to the parties in the herein requested interference, and thus the status of the parties to that interference (e.g., Junior Party, Senior Party, neither party Junior or Senior Party), the issues in the judicial action must first be adjudicated; and, if the interference is declared without prior resolution of the issues of the judicial action, then Jørn Borch SØE will be severely prejudiced in the interference, e.g., by bearing an undue burden of proof.

Thus, suspension of prosecution - until the issues in the judicial action are finally adjudicated - in U.S. application Serial No. 10/779,427 and/or any U.S. application that claims priority or continuing status from U.S. application Serial No. 09/856,819 or PCT/DK99/00664 or is the national stage of PCT/DK99/00664, published as WO 00/32758 - seems to be the mechanism to prevent a premature declaration of interference and severe prejudice in an interference to Jørn Borch SØE.

In addition, the alternative – declaration of the herein requested interference prior to final adjudication of the issues in the judicial action – can result in delays and inefficiencies in that interference and expense to the PTO and the parties. For example, if during the interference Danisco and Jørn Borch SØE are successful in the judicial action, then the interference may have to be redeclared, and perhaps periods therein such as the motions or testimony periods reopened and gone through anew in light of the redeclaration of the interference. This can add delays and expense to the interference and expense to the PTO and parties. Further still, the outcome of the judicial action could even obviate the need for an interference. Thus, suspension of prosecution, as herein requested is in the interests of the potential parties to the interference and the PTO.

Accordingly, it is hereby respectfully requested that prosecution of U.S. application Serial No. 10/779,427 and/or any U.S. application that claims priority or continuing status from U.S. application Serial No. 09/856,819 or PCT/DK99/00664 or is the national stage of PCT/DK99/00664, published as WO 00/32758 be suspended, during the pendency of the judicial action and until final adjudication of the issues in that judicial action; and, thereafter that an interference be declared.

It is additionally noted that the Examiner in the above-captioned applications can consider the information set forth in the attachment hereto for prior art purposes in the above-captioned applications, *inter alia*. See 35 U.S.C. §102(f); *OddzOn Products v. Just Toys*, 122 F.3d 1396 (Fed. Cir. 1997). In *Oddzon* the Federal Circuit held that nonpublic information that an inventor becomes aware of may be combined with other prior art information for purposes of obviousness pursuant to 35 USC 102(f)/103. Since the nature of that which was disclosed to the inventor(s) in the above-captioned applications will be developed in the judicial action, e.g., through discovery, and that which was disclosed may materially impact upon patentability of claims to the present inventor(s) (without Jørn Borch SØE) in the above-captioned applications, this too compels suspension of prosecution in the above-captioned applications during pendency of the judicial action and until final adjudication of the issues in the judicial action.

To any extent a Petition is required for any of the herein requests, or the granting thereof, this paper is to serve as such a Petition.

To any extent a fee is required for the consideration or granting of any of the herein requests or for any Petition required for any of the herein requests (which Petition this paper is to serve as), or the granting thereof, the Commissioner is hereby authorized to charge such a fee, or credit any overpayment in fees, to Deposit Account No. 50-0320.

Indeed, more generally, any fee occasioned by this paper or by any of the herein requests, or for granting of any of the herein requests, or for any Petition required for any of the herein requests (which Petition this paper is to serve as), or the granting thereof, the Commissioner is hereby authorized to charge such a fee, or credit any overpayment in fees, to Deposit Account No. 50-0320.


Furthermore, this paper is presented, and the herein requests made (or if this paper is also considered a Petition, this Petition is made), pursuant to any or all applicable Rules and Sections of the Statute.

CONCLUSION

The suspension of the prosecution of the above-captioned applications during the pendency of the judicial action until final adjudication of the issues therein, with an interference declared, advantageously after final adjudication of the issues in the judicial action, are believed to be in order; and, such relief is respectfully requested.

Respectfully submitted,

Frommer Lawrence & Haug LLP
Attorneys For Danisco A/S and Jørn Borch SØE,



By: Thomas J. Kowalski
Registration No. 32,147
Angela M. Collison
Registration No. 51,107
Tel 212-588-0800
Fax 212-588-0500

IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK

JUDGE SWAIN

DANISCO A/S and JØRN BORCH SØE


Plaintiffs,

-against-

NOVO NORDISK A/S AND NOVOZYMES A/S

Defendants.

CIVIL ACTION NO. 04



COMPLAINT AND DEMAND FOR JURY TRIAL

Plaintiffs, Danisco A/S ("Danisco") and Jørn Borch Sørensen ("Sørensen"), by and through their undersigned attorneys, for their Complaint against Defendants Novo Nordisk A/S ("Novo Nordisk") and Novozymes A/S ("Novozymes") (individually and collectively "Defendants"), allege as follows:

STATEMENT OF THE CASE

This is an action for correction of inventorship under 35 U.S.C. §§ 116, 256 and in equity; for unfair competition pursuant to the Lanham Act under 15 U.S.C. § 1125(a); and for pendant claims under New York law based on Defendants' failure to name Sørensen as an inventor on International Application No. PCT/DK99/00664 entitled "Lipolytic Enzyme Variants" ("the PCT Application"), now published as International Publication No. WO 00/32758, and corresponding U.S. Patent Application Serial No. 09/856,819 ("the '819 Application"). Danisco also seeks a declaration that Sørensen is an inventor on the PCT Application, the '819 Application, and any other U.S. Patent Application and U.S.

Patent and any other patent applications and patents within the jurisdiction of this Court, prosecuted or owned by the Defendants as assignee and corresponding to or claiming priority or continuing status from the PCT Application, the '819 Application or any other patent application that contains or claims subject matter invented by S  . Danisco further seeks an Order from this Court directing the Defendants to add S   as an inventor on the PCT Application, the '819 Application, and any other U.S. Patent Application and U.S. Patent and any other patent applications and patents within the jurisdiction of this Court, prosecuted or owned by the Defendants as assignee and corresponding to or claiming priority or continuing status from the PCT Application, the '8 19 Application or any other patent application that contains or claims subject matter invented by S  .

PARTIES

1. Danisco is a corporation duly organized and existing under the laws of the Denmark, having an office and principal place of business at Langebrogade 1, P.O. Box 17, DK-1001, Copenhagen K, Denmark. Danisco is doing business in New York at 440 Saw Mill River Road, Ardsley, NY 10502 through its subsidiaries and through its Registered Agent, CSC, 1177 Ave of the Americas, 17th Floor, NY NY 10036-2721.

2. S   is an employee of Danisco and resides at Orovaegst 11, 838 1 Mundelstrup, Denmark. S   was an employee of Danisco at all times relevant such that he had an obligation to assign his inventions to Danisco.

3. Upon information and belief, Novo Nordisk is a corporation organized and existing under the laws of Denmark, having an office and principal place of business at Novo Alle, DK-2880 Bagsvaerd, Denmark. Upon information and belief, Novo Nordisk is also located and doing business at 405 Lexington Avenue, Suite 6400, New York, NY

10174-6401, in this judicial district.

4. Upon information and belief, Novo Nordisk demerged its enzyme business in or about 2000 into an independent legal entity, Novozymes.

5. Upon information and belief, Novozymes is a corporation organized and existing under the laws of Denmark, having an office and principal place of business at 36 Kragshøjvej, DK- 2880 Bagsværd, Denmark. Upon information and belief, Novozymes is also located and doing business at 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401, in this judicial district.

JURISDICTION AND VENUE

6. This Court has subject matter jurisdiction over the correction of inventorship, Lanham Act and New York state-law claims set forth below by virtue of 15 U.S.C. § 1121, 28 U.S.C. §§ 1331, 1338(a), 1338(b) and 1367. The Court also has subject matter jurisdiction under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

7. This Court has personal jurisdiction over Defendants due to, *inter alia*, their presence doing business in New York.

8. Venue is proper in this district under 28 U.S.C. § 1391(b) and (c).

BACKGROUND

9. In the course of his employment with Danisco, Danisco's employee Søren conceived and reduced to practice, *inter alia*, a process for using lipases that selectively hydrolyzed long-chain triglycerides over short-chain triglycerides and that exhibited high activity for phospholipids and glycolipids.

10. Beginning in or about 1997, Danisco and Defendants entered into

discussions regarding a proposed cooperative arrangement concerning lipases for use in making dough systems (the "Arrangement"). In connection with the Arrangement, Danisco and Defendants signed a cooperation agreement ("the cooperation agreement") on April 2, 1998 and March 24, 1998, respectively. The cooperation agreement's effective date was December 1, 1997, with a term of 24 months.

11. Pursuant to the Arrangement, Defendants would supply Danisco with samples of lipases, on information and belief from their existing inventory of lipases, and Danisco would, in turn, select product candidates from its research through screening and testing the lipases. The lipase samples were to be supplied according to Danisco's disclosure to Defendants of the desired characteristics, e.g., high activity for phospholipids and glycolipids.

12. Pursuant to the Arrangement, Danisco provided highly confidential and proprietary information to Defendants, and Defendants had a duty to maintain that information as confidential and proprietary to Danisco. Danisco disclosed to Defendants confidential information and know-how about lipases, including, *inter alia*, information relating to Danisco's knowledge and experience with the ability of lipases to selectively hydrolyze long-chain triglycerides over short-chain triglycerides and to exhibit high activity for phospholipids and glycolipids.

13. Danisco used its know-how and research experience to, *inter alia*, test lipases that selectively hydrolyzed long-chain triglycerides over short-chain triglycerides and that exhibited high activity for phospholipids and glycolipids. Pursuant to the Arrangement, Danisco disclosed, *inter alia*, those tests and results thereof to Defendants.

14. Defendants had a duty to name Søe as an inventor on any patents or patent

applications that contain or claim subject matter invented by S e.

COUNT I

Correction of Inventorship

15. Plaintiffs restate and re-allege the allegations set forth in paragraphs 1 through 14, as if fully set forth herein.

16. On information and belief, on November 29, 1999, the Defendants filed the PCT Application. The PCT application does not name S e as an inventor. A copy of the PCT Application published as WO 00/32758 is attached hereto as Exhibit 1.

17. On information and belief, the PCT Application corresponds to the '8 19 Application pending in the United States Patent and Trademark Office.

18. The PCT and '819 Applications claim (i) a method for preparing dough with lipases that selectively hydrolyze long-chain triglycerides over short-chain triglycerides and that exhibit high activity for phospholipids and glycolipids, and (ii) a method of making a dough product using such lipases.

19. Upon information and belief, Defendants are the assignee(s) of all rights, title and interest in and to the PCT and '819 Applications.

20. The PCT and '8 19 Applications contain Danisco's confidential information, including the inventions by S e.

21. S e is an inventor of subject matter claimed in the PCT and '8 19 Application and has an obligation to assign his invention to Danisco.

22. Before filing this action, Danisco informed Defendants, *inter alia*, that the concept of developing, selecting or using an enzyme with certain characteristics, including the capability to hydrolyze phospholipids, the capability to hydrolyze

digalactosyl diglyceride, and relatively high activity toward triglycerides with long chain fatty acids as compared to triglycerides with short chain fatty acids, including the use of an enzyme with said characteristics for preparing doughs (e.g. for baking purposes), originated from Danisco, was disclosed to Defendants pursuant to the Arrangement and, together with any patent application relating thereto, is the property of Danisco.

23. On information and belief, Defendants are aware of Danisco's claims but refuse to acknowledge S e's rights as an inventor and/or Danisco's rights as assignee to the claimed methods in the PCT and '819 Applications for (i) preparing dough with lipases that selectively hydrolyze long-chain triglycerides over short-chain triglycerides and that exhibit high activity for phospholipids and glycolipids, and (ii) making a dough product using such lipases.

24. Specifically, in a letter dated September 9, 2000, the Defendants admitted: "It is correct that representatives of Danisco have, during the Lipase Collaboration, disclosed to Novo Nordisk certain information on developing, selecting or using enzymes. . ." for use in preparing doughs and making dough products.

25. Before filing this action, Danisco requested from Defendants "firm and solid evidence, in the form of copies of signed laboratory journals or the like, to prove firm that the inventive concept was developed by [the Defendants] independently of information received from Danisco." Defendants have not provided the requested evidence to Danisco. Consequently, Danisco has been forced to bring this action.

26. S e has a reputational interest in being named or recognized as an inventor on the PCT and '819 Applications.

27. The public has an interest in assuring the correct naming of inventors on

patents.

28. Danisco has an ownership interest in the PCT and '819 Applications as well as a substantial pecuniary interest in any patents issuing therefrom.

29. Danisco has filed a patent application concerning the subject matter invented by Søe with the United States Patent and Trademark Office. Neither Danisco nor Søe may perfect a claim of priority to the PCT Application pursuant to 35 U.S.C. § 120 until Søe is rightfully named as an inventor thereon. If a claim of priority to the PCT Application is not perfected, Danisco may lose all rights, title and interest in and to its inventions.

30. Danisco has filed papers with the Patent and Trademark Office requesting declaration of an interference between the '819 Application and Danisco's pending patent application. If Danisco cannot perfect its claim of priority to the PCT Application, Danisco may face an inappropriate, undue burden of proof in that interference and lose all rights, title and interest in and to its inventions.

31. As a direct and proximate result of Defendants' wrongful acts complained of above, Danisco has been severely harmed by virtue of loss of control over its confidential information, know-how and technology, loss of competitive advantage in the industry and loss of the ability to protect its invention rights. Plaintiffs seek damages in an amount to be determined at trial, and correction of inventorship under 35 U.S.C. §§ 116,256 and in equity.

COUNT II

Declaration that Jsrn Borch See Is an Inventor

32. Danisco restates and re-alleges the allegations set forth in paragraphs 1

through 31, as if fully set forth herein.

33. An actual controversy exists between Danisco and Defendants concerning inventorship of the PCT and '819 Applications.

34. If Danisco cannot perfect its claim of priority to the PCT Application, Danisco may face an inappropriate, undue burden of proof in an interference and risks losing all rights, title and interest in and to its inventions.

35. Plaintiffs seek a declaration that Sørensen is an inventor of the subject matter of the PCT Application, the '819 Application, and any other U.S. Patent Application and U.S. Patent and any other patent applications and patents within the jurisdiction of this Court, prosecuted or owned by the Defendants as assignee and corresponding to or claiming priority or continuing status from the PCT or '819 Applications, or from any other patent application that contains or claims subject matter invented by Sørensen. Plaintiffs further seek an Order by this Court directing the Defendants to add Sørensen as an inventor on the patent application(s) and patent(s) described above.

COUNT III

Unfair Competition

36. Plaintiffs restate and re-allege the allegations set forth in paragraphs 1 through 35, as if fully set forth herein.

37. Upon information and belief, Defendants have disclosed and used Danisco's technology and confidential information outside of the terms of the Arrangement. Upon information and belief, Defendants have filed patent applications, including without limitation the '819 Application, that disclose, contain, rely upon, and seek to secure for themselves invention rights in Danisco's confidential information,

know-how and technology.

38. Defendants seek to gain a competitive edge over Danisco in the industry by virtue of Defendants' unfair competition against Danisco.

39. Defendants have, through their actions and as a result of their misappropriation of Danisco's confidential information, know-how and technology "passed off" Danisco's confidential information, know-how and technology as Defendants' own.

40. On information and belief, Defendants' wrongful acts have created an expectation of profit based upon Danisco's confidential information, know-how and technology.

41. As a direct and proximate result of Defendants' wrongful acts, Danisco has been severely harmed by virtue of loss of control over its confidential information, know-how and technology, loss of competitive advantage in the industry and loss of the ability to protect its invention rights. Danisco seeks damages for Defendants' unfair competition in an amount to be determined at trial.

COUNT IV

Unjust Enrichment

42. Plaintiffs restate and re-alleges the allegations set forth in paragraphs 1 through 41, as if fully set forth herein.

43. Upon information and belief, Defendants have used Danisco's confidential information, know-how and technology as Defendants' own, and to obtain and/or apply for patent protection on technology and intellectual property belonging to Danisco.

44. To the extent that Defendants have profited from these actions,

Defendants have been unjustly enriched at Danisco's expense. Furthermore, if a patent issues from the '819 Application, or from any other U.S. or other Patent Application within the jurisdiction of this Court, prosecuted or owned by the Defendants as assignee and corresponding to or claiming priority or continuing status from the PCT Application, the '8 19 Application, or any other patent application that contains or claims subject matter invented by S e, without Sse named thereon as an inventor, the Defendants are unjustly enriched.

45. As recompense for Defendants' wrongful acts complained of above, Danisco demands a constructive trust over Defendants' profits and revenue relating to any misuse of Danisco's confidential information, know-how and technology.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully request the following relief:

- A. A judgment that Defendants are liable for each claim asserted above;
- B. A judgment directing Defendants to pay Danisco damages suffered as a result of Defendants' wrongful acts complained of herein at an amount to be determined at trial;
- C. A judgment directing Defendants to pay Danisco all appropriate punitive or exemplary damages as allowed by law;
- D. A declaration that S e is an inventor on the PCT Application, the '8 19 Application, and any other U.S. Patent Application and U.S. Patent and any other patent applications and patents within the jurisdiction of this Court, prosecuted or owned by the Defendants as assignee and corresponding to or claiming priority or continuing status from the PCT Application, the ' 8 19 Application, or any other patent application that

contains or claims subject matter invented by S e.

E. A judgment directing Defendants to add S e as an inventor on the PCT Application, the '819 Application, and any other U.S. Patent Application and U.S. Patent and any other patent applications and patents within the jurisdiction of this Court, prosecuted or owned by the Defendants as assignee and corresponding to or claiming priority or continuing status from the PCT Application, the '819 Application, or any other patent application that contains or claims subject matter invented by S e.

F. An award of costs and expenses in this action consistent with, *inter alia*, 35 U.S.C. §285 because this is an exceptional case;

G. An award of Danisco's reasonable attorneys' fees incurred in this matter;

H. An award of pre- and post-judgment interest on all damages awarded herein at the rate provided by law; and

I. Such other and further relief as this Court deems just and proper.

DEMAND FOR JURY TRIAL


Plaintiffs demand a trial by jury of all issues triable as of right by a jury.

Dated: November 20, 2001

New York, New York

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

By: 

Barry S. White (BW8332)

Thomas J. Kowalski (TK7827)

Tedd W. Van Buskirk (TVB8766)

Christian M. Smolizza (CS2412)

745 Fifth Avenue

New York, New York 1015 1

Tel: (212) 588-0800

Attorneys for Plaintiffs

Danisco A/S and Jørn Borch Sae

Of Counsel:

Richard Russeth, Esq.

Eileen Gill, Esq.

Danisco A/S

Legal Department

440 Saw Mill River Road

Ardsley, NY 10502

EXHIBIT 1

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 9/20 // C11D 3/386, A21D 8/04, A23L 1/105		A1	(11) International Publication Number: WO 00/32756
			(43) international Publication Date: 8 June 2000 (08.06.00)
(21) International Application Number: PCT/DK99/00664		Tagensvej 81. 3. DK-2200 Copenhagen (DK). GLAD, Sanne, Schrøder [DK/DK]; Viggo Barfoeds Allé 59. DK-2840 Holte (DK). BUDOLFSEN, Gitte [DK/DK]; Lyevej 3. 3.tv., DK-2000 Frederiksberg (DK). (74) Common Representative: NOVO NORDISK A/S; Enzyme Business Patents, Novo Allé, DK-2880 Bagsvaerd (DK). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 29 November 1999 (29.11.99)			
(30) Priority Data: PA 1998 01572 27 November 1998 (27.11.98) DK 60/111,430 8 December 1998 (08.12.98) US PA 1999 00391 22 March 1999 (22.03.99) DK 60/126,914 29 March 1999 (29.03.99) US PA 1999 01481 15 October 1999 (15.10.99) DK 60/160,735 22 October 1999 (22.10.99) u s			
(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): BOJSEN, Kirsten [DK/DK]; Bakkedal 5, DK-2900 Hellenup (DK). SVENDSEN, Allan [DWDK]; Bakkeledet 28, DK-3460 Birkerød (DK). FUGLSANG, Klaus, Crone [DK/DK]; Poppelhøj 43. DK-2990 Nivå (DK). SHAMKANT, Arrant, Patkar [DK/DK]; Christoffers Allé 91. DK-2880 Lyngby (DK). BORCH, Kim [DK/DK]; Klerkegade 12 2tv, DK-1808 Copenhagen (DK). VIND, Jesper [DK/DK]; Bagsvaerdvej 115, DK-2880 Lyngby (DK). PETRI, Andreas [DK/DK];			
(54) Title: LIPOLYTIC ENZYME VARIANTS (57) Abstract The substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzyme variants with a modified amino acid sequence with a substrate specificity which can be tailored for specific uses.			

LIPOLYTIC ENZYME VARIANTS

FIELD OF THE INVENTION

The present invention relates to a method of altering the substrate specificity of a lipolytic enzyme by modifying the amino acid sequence, and to lipolytic enzyme
5 variants obtained by such modification. The invention also relates to a screening method for lipolytic enzymes.

BACKGROUND OF THE INVENTION

Lipolytic enzymes (such as lipases and phospholipases) are capable of hydrolyzing carboxylic ester bonds in a substrate to release carboxylic acids. The hydrolytic activity on different ester bonds is important for the usefulness of the lipolytic
10 enzyme in various industrial applications.

Thus, enzymes with a high phospholipase activity are useful in a wide range of applications such as baking (US 4,567,046), filtration of wheat starch hydrolysate (US 5264,367) and treatment of vegetable oil to reduce the content of phospholipid (US 5264,367). For the treatment of vegetable oil, the enzyme should have a low
15 lipase activity, i.e. a low hydrolytic activity towards ester bonds in triglycerides..

WO 98145453 indicates that an enzyme with a high hydrolytic activity on digalactosyl diglyceride (DGDG) is useful in baking.

It is well known to add a lipase to laundry detergents to aid in the removal of greasy soils (e.g. EP 258,068).
20

The release of short-chain fatty acids as free fatty acids (FFA) may be desirable for flavor development in food products, e.g. in cheese ripening (M. Hanson, ZFL, 41 (IO), 664-666 (1990)).

The three-dimensional (3D) structure of several lipolytic enzymes is known, and several structures are known to contain a so-called "lid" which may be in an open or closed state covering the active site. Brady et al., Nature, 343, 767-770 (1990). Brzozowski A M et al., Nature, 351, 491 (1991). Derewenda et al., Biochemistry, 31 (5), 1532-1541 (1992).
25

F. Hara et al., JAOCS, 74 (9), 112932 (1997) indicates that some lipases have a certain phospholipase activity, whereas most lipases have little or no activity on phospholipids. Thus, phospholipase activity has been described in the lipases from guinea pig pancreas, *Fusarium oxysporum* and *Staphylococcus hyicus*, and attempts have been made to relate the phospholipase activity to the structure of the
30

lipase. WO 98/26057; M.D. van Kampen et al., Chemistry and Physics of Lipids, 93 (1998), 39-45; A. Hjorth et al., Bio- chemistry 1993, 32, 4702-4707.

The prior art has described the effect on chain-length selectivity by amino acid substitutions in a lipase from *Rhizopus delemar*. Thus, R. D. Joerger et al., Lipids, 29 (6), 377-384 (1994) indicates that the variants F95D, F112W and V209W have an altered preference to C₄ and C₈ acids. R. R. Klein et al., JAOCS, 74 (II), 140 I-1407 (1997) shows that the variant V206T+F95D has a higher selectivity for C₈ acid. R. R. Klein et al., Lipids, 32 (2), 123-130 (1997) indicates that the variants V209W+F112W, V94W and F95D+F214R have a higher hydrolytic activity towards C₄ and C₈ acids, and suggests that structural determinants for medium-chain length specificity may reside in the distal end of the acyl binding groove.

SUMMARY OF THE INVENTION

The inventors have found that the substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence in a defined region of the lipolytic enzyme, so as to increase the level of a desired activity or to decrease the level of an undesired activity. Thus, the inventors have developed lipolytic enzymes with a modified amino acid sequence (hereinafter called lipolytic enzyme variants, or variants for short) with a substrate specificity which can be tailored for specific uses.

Accordingly, the invention provides a method of producing a lipolytic enzyme variant and lipolytic enzyme variants prepared by the method. The method comprises:

- a) selecting a substrate and an ester bond of interest,
- b) selecting a parent lipolytic enzyme,
- c) selecting at least one amino acid residue in a region near the active site, near the C-terminal or in the lid region of the parent lipolytic enzyme as described below,
- d) making alterations each of which is an insertion, a deletion or a substitution of the amino acid residue,
- e) optionally, making alterations each of which is an insertion, a deletion or a substitution of an amino acid residue at one or more positions other than c),
- f) preparing the resulting variant,
- g) testing the activity of the variant on the ester bond in the substrate, and
- h) selecting a variant having an altered activity on the ester bond.

Thus, in one aspect, the parent lipolytic enzyme has an alcohol binding site having a glycerol part with an sn2 position, and the amino acid alteration is within 10 Å of the C atom at the sn2 position of the glycerol part of a substrate triglyceride.

5 In another aspect, the parent lipolytic enzyme has a structure comprising a catalytic triad consisting of an active Ser, an active Asp and an active His residue, and the amino acid to be altered is either located between the active His residue of the catalytic residue and the C-terminal, or belongs to a set E defined by the following steps:

10 i) aligning the structure of the lipolytic enzyme with *Rhizomucor miehei* lipase structure 4TGL comprising a catalytic triad and an inhibitor phosphorus atom (4TGL-inhP), so as to minimize the sum of squares of deviation between atoms of the catalytic triads of the two structures,

15 ii) defining a set A consisting of atoms of the lipolytic enzyme inside a sphere of radius 18 Å with center at 4TGL-inhP,

20 iii) forming a first plane defined by 4TGL-inhP, the C α atom of the active Ser residue of the parent lipolytic enzyme, and the C α atom of the active Asp residue of the parent lipolytic enzyme and defining a set B as a subset of set A consisting of atoms on the same side of the first plane as the C α atom of the active His residue of the parent lipolytic enzyme,

25 iv) forming a second plane defined by 4TGL-inhP, the C α atom of the active Ser residue of the parent lipolytic enzyme, and the C α atom of the active His residue of the parent lipolytic enzyme and defining a set C as a subset of set A consisting of atoms on the opposite side of the second plane from the C α atom of the active Asp residue of the parent lipolytic enzyme,

v) forming a set D consisting of atoms belonging to the union of sets B and C, and having a solvent accessibility of 15 or higher, and

30 vi) forming set E consisting of amino acid residues in the structure which comprise an atom belonging to set D or an atom belonging to the union of sets B and C and located less than 3.5 Å from an atom belonging to set D,

In a third aspect, the lipolytic enzyme has an active site comprising an active His residue, and the alteration is made in the amino acid sequence between the active His residue and the C-terminal.

35 In yet another aspect of the invention, the amino acid alteration is made among the 10 amino acid residues at the C-terminal.

In a further aspect, the parent lipolytic enzyme has a lid, and the alteration is made in the lid.

The invention also provides a DNA sequence encoding the variant, an expression vector comprising the DNA sequence, a transformed host cell harboring the DNA sequence or the expression vector, and to a method of producing the variant by cultivating the transformed host cell so as to produce the variant and recovering the variant from the resulting broth. Further, the invention provides uses of the variants.

The inventors have also found that a lipolytic enzyme which has lipase and phospholipase activity as well as activity on digalactosyl diglyceride is particularly effective for use in baking, and they designed a screening method for lipolytic enzymes by testing for these activities.

BRIEF DESCRIPTION OF DRAWINGS

Fig. 1 shows an alignment of lipase sequences.

DETAILED DESCRIPTION OF THE INVENTION

Altered activity on selected ester bond in substrate

Compared to the parent lipolytic enzyme, the invention aims to alter the activity on at least one selected ester bond in at least one substrate, i.e. to increase a desired activity, decrease an undesired activity or to change the substrate specificity by decreasing the ratio of an undesired activity to a desired activity.

Thus, an enzyme with increased phospholipase activity may be useful, e.g., in baking or in purification of vegetable oil. It may be desired to increase the hydrolytic activity on digalactosyldiglyceride (DGDG) for use in baking.

It may be desired to increase the lipase activity for any industrial use where lipases are used. For use in detergents or baking it may be desired to increase the activity on long-chain (C_{16} - C_{20}) triglycerides, and it may be desired to increase the specificity for long-chain fatty acids by decreasing the ratio of activity on short-chain or medium-chain (C_4 - C_8) fatty acids to the activity on long-chain fatty acids.

For use in, or for use in flavor development in food products (such as cheese ripening) it may be desired to increase the lipase activity on short-chain or medium-chain (C_4 - C_8) triglycerides.

For use as a phospholipase in purification of vegetable oil, it may be desired to decrease the ratio of lipase activity on long-chain (C_{16} - C_{20}) triglycerides to the phospholipase activity.

Parent lipolytic Enzyme

5 The lipolytic enzyme to be used in the present invention is one that can hydrolyze ester bonds. Such enzymes include, for example, lipases, such as triacylglycerol lipase (EC 3.1.1.3), lipoprotein lipase (EC 3.1 .1.34), monoglyceride lipase (EC 3.1. 1.23), lysophospholipase, ferulic acid esterase and esterase (EC 3.1 .1.1, EC 3.1 .1.2). The numbers in parentheses are the systematic numbers assigned by the
10 Enzyme Commission of the International Union of Biochemistry in accordance with the type of the enzymatic reactivity of the enzyme.

The parent lipolytic enzyme may be prokaryotic, particularly a bacterial enzyme, e.g. from *Pseudomonas*. Examples are *Pseudomonas* lipases, e.g. from *P. cepacia* (US 5,290,694, pdb file 1OIL), *P. glumae* (N Frenken et al. (1992), Appl. En-
15 vir. Microbiol. 58 3787-3791, pdb files 1TAH and 1QGE), *P. pseudoalcaligenes* (EP 334 462) and *Pseudomonas* sp. strain SD 705 (FERM BP-4772) (WO 95/06720, EP 721 981, WO 96/27002, EP 812 910). The *P. glumae* lipase sequence is identical to the amino acid sequence of *Chromobacterium viscosum* (DE 3908131 A1). Other examples are bacterial cutinases, e.g. from *Pseudomonas* such as *P. mendocina*
20 (US 5,389,536) or *P. putida* (WO 88/09367).

Alternatively, the parent lipolytic enzyme may be eukaryotic, e.g. a fungal lipolytic enzyme such as lipolytic enzymes of the *Humicola* family and the *Zygomycetes* family and fungal cutinases.

Examples of fungal cutinases are the cutinases of *Fusarium solani pisi* (S.
25 Longhi et al., Journal of Molecular Biology, 268 (4), 779-799 (1997)) and *Humicola insolens* (US 5,827,719).

The *Humicola* family of lipolytic enzymes consists of the lipase from *H. lanuginosa* strain DSM 4109 and lipases having more than 50 % homology with said lipase. The lipase from *H. lanuginosa* (synonym *Thermomyces lanuginosus*) is de-
30 scribed in EP 258 068 and EP 305 216, and has the amino acid sequence shown in positions 1-269 of SEQ ID NO: 2 of US 5,869,438.

The *Humicola* family also includes the following lipolytic enzymes: lipase from *Penicillium camembertii* (P25234), lipase/phospholipase from *Fusarium oxysporum* (EP 130064, WO 98/26057), lipase from *F. heterosporum* (R87979), lyso-
35 phospholipase from *Aspergillus foetidus* (W33009), phospholipase A1 from *A. oryzae* (JP-A 10-155493), lipase from *A. oryzae* (D85895), lipase/ferulic acid es-

terase from *A. niger* (Y09330), lipase/ferulic acid esterase from *A. tubingensis* (Y09331), lipase from *A. tubingensis* (WO 98/45453), lysophospholipase from *A. niger* (WO 98/31790), lipase from *F. solanii* having an isoelectric point of 6.9 and an apparent molecular weight of 30 kDa (WO 96/1 8729).

The *Zygomycetes* family comprises lipases having at least 50 % homology with the lipase of *Rhizomucor miehei* (P19515). This family also includes the lipases from *Absidia reflexa*, *A. sporophora*, *A. corymbifera*, *A. blakesleeana*, *A. griseola* (all described in WO 96/13578 and WO 97/27276) and *Rhizopus oryzae* (P21811). Numbers in parentheses indicate publication or accession to the EMBL, GenBank, GeneSeq or Swiss-Prot databases.

It is of particular interest to derive a variant with phospholipase activity from a parent lipolytic enzyme having no or very little phospholipase activity, e.g. corresponding to a ratio of phospholipase activity to lipase activity below 0.1 PHLU/LU or below 50 PHLU/mg.

Alteration near alcohol binding site

As already stated, the amino acid sequence of the parent lipolytic enzyme may be modified at a position which near the glycerol part of a substrate triglyceride. This region will be referred to as the "alcohol binding site" of the lipase; it is described in Brzozowski A M et al., Nature, 351: 491 (1991); Uppenberg et al., Biochemistry, 1995, 34, 16838-16851; A. Svendsen, Inform, 5(5), 619-623 (1994).

For the *Rhizomucor miehei* lipase, the extent of the alcohol binding site can be found from the PDB file "5tgi.pdb" available in Structural Classification of Proteins (SCOP) on the Internet, at <http://www.rcsb.org/pdb/>, showing the complex with the inhibitor n-hexylphosphonate ethyl ester which mimics the substrate. It is described in Derewenda et al. (supra), Brzozowski et al. (supra) and Brady et al. (supra). The sn2 position of this model is the atom CE2.

The variant typically contains no more than 10 alterations in the alcohol binding site, e.g. 1, 2, 3, 4, 5 or 6 alterations.

The alteration may particularly be in that part of the alcohol binding site which comes within 20 positions (e.g. within 10 positions) of the C-terminal.

As already stated, the amino acid sequence of the parent lipolytic enzyme may be modified at a position which is within 10 Å (e.g. within 8 Å, particularly within 6 Å) of the C atom at the sn2 position of the glycerol part of a substrate triglyceride. The following amino acid positions lie within 10 Å of the sn2 position in the *Rhizomucor miehei* lipase: 25, 28, 80-84, 88, 143-146, 175, 203, 205, 254-255, 257-259, 264-

267. The following are within 8 Å: 81-83, 144, 257-258, 265-267, and the following within 6 Å: 82, 144, 257, 266.

In the *Humicola lanuginosa* lipase, the following positions are within 10 Å of the sn2 position: 18, 21, 81-85, 89, 145-148, 172, 201, 203, 255-256, 258-260, 264-
5 267. The following are within 8 Å: 82-84, 89, 146, 258-259, 265-267, and the following within 6 Å: 83, 146, 258, 266.

Alteration near catalytic triad

As already stated, in one aspect the parent lipolytic enzyme has a structure comprising a catalytic triad consisting of an active Ser, an active Asp and an active
10 His residue, and the amino acid to be altered belongs to a set defined by a certain procedure described above. The structure may be an open or a closed structure, and it may or may not include a substrate or an inhibitor.

The procedure is conveniently performed by use of software such as MSI's Insight II. It involves alignment with 4TGL, a crystal structure of the lipase from *Rhizomucor miehei* inhibited irreversibly by diethyl p-nitrophenyl phosphate. This is
15 available in Structural Classification of Proteins (SCOP) on the Internet, at <http://www.rcsb.org/pdb/>, and is described in Derewenda et al. (supra). The *Rhizomucor miehei* lipase comprises a catalytic triad consisting of the amino acid residues S144, D203 and H 257.

20 For the *Humicola lanuginosa* lipase, the structure 1tib may be used; it is available in Structural Classification of Proteins (SCOP) on the Internet. Using this structure, the set defined by the procedure includes the following positions: 10-23, 26, 40, 55-64, 80-87, 116-117, 119, 145-149, 151, 168, 170, 194, 196-201, 220-222, 224-227, and 254-269.

25 Alteration between at C-terminal side of the active His residue

As stated above, one or more alterations may be made in the amino acid sequence between an active His residue and the terminal, specifically among the 12 amino acids at the C-terminal side of the active His.

The *Humicola lanuginosa* lipase has an active His at H258 and the C-terminal at L269, so this region includes positions 259-269. The *P. cepacia* lipase
30 has an active H286 and the C-terminal at residue 297, so the region includes residues 287-297.

Alteration near C-terminal

As stated above, one or more alterations may be made within 10 amino acid positions from the C-terminal of the mature protein,

or at positions corresponding to such positions in the *H. lanuginosa* lipase, i.e. positions 260-269 of the *H. lanuginosa* lipase. Corresponding positions may be found by alignment of the two sequences as described later in this specification.

The lipolytic enzyme variant may be truncated by deleting amino acid residues corresponding to the first 1, 2, 3, 4, 5 or 6 positions at the C-terminal. A truncated variant may have improved thermostability.

Alternatively, the variant may carry a peptide extension at the C-terminal and/or the N-terminal. The C-terminal extension may consist of i-10 amino acid residues, e.g. A, P, AG, DG, PG, AGG, PVGF, AGRF, PRGF, AGGF or AGGFS; or it may consist of 40-50 residues, e.g., consisting of the 48 C-terminal residues of the *Fusarium oxysporum* lipase AGGFSWRRYRSAESVDKRAMTDAELEKKLNSY-VQMDKEYVKNNQARS. The C-terminal extension may increase the phospholipase activity.

Some alterations in the region overlapping with the alcohol binding site are described below.

A specific alteration is a substitution at a position corresponding to G266 in the *Humicola lanuginosa* lipase, specifically with an amino acid of intermediate size, e.g. A, C, D, N, L, I, S, T, P or V. Such alteration alone has been found sufficient to increase the phospholipase activity.

Other specific alterations are such that alter the tertiary structure, e.g. by introducing bulky side chains or by disrupting the bond angles, e.g. by introducing Pro. Such alterations may be made at positions corresponding to positions G263, L264, 1265, T267 or L269 in the *Humicola lanuginosa* lipase. Some specific substitutions are G263A,E,Q,R; L264A,C,P,Q; I265L,N,T; T267A,Q or L269N.

Alteration in lid

As stated above, the amino acid sequence of the prent lipolytic enzyme may be modified in the lid region of the parent lipolytic enzyme. This region is described in Brady et al., *Nature* 343, 1990, pp. 767-770 and in Brzozowski A M et al., *Nature*, 351: 491 (1991). In the *H. lanuginosa* lipase, the lid is located at positions 80-100, and the modification may particularly be made at positions 82-98, e.g. 91-98.

The variant typically contains no more than 5 alterations in the lid region; it may contain 0, 1, 2 or 3 alterations. A specific alteration is a substitution of an amino acid corresponding to G91, L93, N94, D96, K98, L97 and/or E99 in the *Humicola lanu-*

ginosa lipase with a neutral or positively charged amino acid, e.g. a substitution corresponding to G91A,T, L93K, N94D, D96S,W,G, L97Q, K98D,F,E and/or E99K,D.

Specifically, a variant with an alteration in the lid region also contains one or
5 more alterations near the catalytic triad, near the substrate binding site or near the C-terminal.

Lipolytic enzyme variants

The lipolytic enzyme variant of the invention comprises one or more alterations of an amino acid residue in any of the regions described above. Each alteration
10 may be a deletion or a substitution of the amino acid residue, or it may be an insertion before or after the amino acid residue. If the amino acid residue is at the C-terminal, the insertion may be a C-terminal extension. An insertion typically consists of 1-5 amino acid residues, e.g. 1-2, and a C-terminal extension may consist of 1-50 or 2-10 amino acid residues.

15 The total number of alterations in the above regions is typically not more than 20, e.g. not more than 10 or not more than 5, and there may be as little as 1 or 2 alterations in the above regions.

In addition, the lipolytic enzyme variant of the invention may optionally include other modifications of the parent enzyme, typically not more than 10, e.g. not
20 more than 5 such modifications.

The variant generally has a homology with the parent lipolytic enzyme of at least 80 %, e.g. at least 85 %, typically at least 90 % or at least 95 %.

The variant of the invention may further comprise a peptide extension at the N-terminal, e.g. consisting of 1-15 (particularly 4-10) amino acid residues, and specifically
25 comprising 1, 2 or 3 positively charged amino acids. Some specific N-terminal peptide extensions are AS, SPIRR, E1RP, E1SPIRPRP, E1SPRRP and E1SPIRPRP. Further, any peptide extension described in WO 97/04079 and WO 97/07202 may be used.

Specific variants

30 To prepare variants of a lipolytic enzyme of the *Humicola* family, the amino acid alterations may specifically be made at positions corresponding to 20-25, 56-64, 81-85 or 255-269 in the *Humicola lanuginosa* lipase. Thus, the alteration may be a substitution, deletion or insertion at a position corresponding to A20, Y21, G23, K24, N25, V63, R81, G82, R84, A257, W260, Y261, F262 or G266 (e.g. excluding G23C, K24C, R81 C), a substitution of an amino acid corresponding to C268 or L269.
35

Some specific alterations are substitutions corresponding to the following in *H. lanuginosa* lipase: Y21V/I/L/A/G/M/W/P/F/N/Q/S/T, V60V/I/L/A/G/M/W/P/F/N/Q/S/T, G61 V/I/L/A/G/M/W/P/F/N/Q/S/T, D62E/A/V, S83T, R84K/L/W, P256A, G263E,Q,R,F, L264A,C,P,F,G,I, I265L,N,F
 5 G266D/E or T267A,Q,P,S,E, or an insertion corresponding to T267GS or T267GL.

To alter the activity towards short-chain (C₄-C₈) fatty acids in triglycerides, alterations may be made at positions corresponding to Y21, E56, 057, V60, G61, 062, R81, S83, R84, L259, Y261 or G266, e.g. a substitution corresponding to Y21V/I, V60G, D62E/A/V, S83T, R84K/L/W or G266D/E.

10 To increase the activity for DGDG, alterations may be made at positions corresponding to Y21, G23, N26, 057,062, R81, S83, R84, S85, G266, T267 or L269; e.g., two or more such alterations may be made, e.g. together with one or more alterations in the lid region. To increase the phospholipase activity, alterations may be made at positions corresponding to R81, R84, S85, or 263-267, e.g. G266 or T267.

15 To prepare variants of a *Pseudomonas* lipase, amino acid modifications may be made at positions corresponding to 12-13, 16-34, 45-52, 59-66, 68, 86-87, 107-109, 111, 143-153, 155, 157-158, 207-212, 228, 230, 242-249, 264, 279-280, 282-297, 301-302, 304-305, 307-308 in the *P. cepacia* lipase, particularly L17/L17, T18/A18, Y29/Y29, L287/L286, E289/E288, I290/I289, Q292/Q291 or L293/L292 in
 20 the *P. cepacia*/*P. glumae* lipase.

Specific variants of the *H. lanuginosa* lipase are disclosed in the examples. Corresponding alterations may be made in other parent lipolytic enzymes. Further variants may be derived from these by omitting amino acid modifications at positions 1, 106, 186, 225, 232, 237, 239 or 274. Variants with 274S may optionally have a
 25 further C-terminal extension of WRRYR-SAESVDKRAMTDAELEKKLNSYVQMDKEYVKNNQARS (corresponding to the C-terminal of the *F. oxysporum* lipase) in full or truncated form.

Nomenclature for amino acid alterations

The nomenclature used herein for defining mutations is basically as described in WO 92/05249. Thus, G91A indicates substitution of G in position 91 with A. T267A,Q indicates substitution of T at position 267 with A or Q. EI E,D,A indicates that EI is unchanged or is substituted with D or A.

T267stop indicates a stop codon, i.e. deletion of T267 and all following amino acids (i.e. C268 and L269). 270P, 271V indicates a C-terminal extension of PV (i.e. at new positions 270 and 271). -G266 indicates deletion of G at position 266.
 35 Parentheses indicate that the alteration is optional, or in examples that the alteration

is uncertain. SPIRR indicates an N- terminal extension. 0266 may refer to the position or to substitution with any amino acid (except D).

E1SPPCGRRP or SPPCGRRP(- E) indicates a substitution of EI with SPPCGRRP. i.e. a peptide addition at the N-terminal. T267GS indicates a substitution of T267 with GS, or in other words the substitution T267G and an insertion of S between G267 and C268.

Homology and alignment

For purposes of the present invention, the degree of homology may be suitably determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-45), using GAP with the following settings for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1.

In the present invention, corresponding (or homologous) positions in the lipase sequences of *Rhizomucor miehei* (rhimi), *Rhizopus delemar* (rhidl), *Thermomyces lanuginosa* (former; *Humicola lanuginosa*) (SP400), *Penicillium camembertii* (Pcl) and *Fusarium oxysporum* (FoLnp11), are defined by the alignment shown in Figure 1.

To find the homologous positions in lipase sequences not shown in the alignment, the sequence of interest is aligned to the sequences shown in Figure 1. The new sequence is aligned to the present alignment in Fig. 1 by using the GAP alignment to the most homologous sequence found by the GAP program. GAP is provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-45). The following settings are used for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1.

30 Variants with phospholipase activity

As described above, the variant of the invention may have a higher phospholipase activity than the parent lipolytic enzyme. By the monolayer method described later in this specification, the variant may have a phospholipase activity of at least 0.1 nmol/min at pH 5.

By the PHLU method described later in this specification, the variant may have a phospholipase activity of at least 100 PHLU/mg (mg of pure enzyme protein), particularly at least 500 PHLU/mg. The variant has a ratio of phospholipase activity to lipase activity (both measured at pH 7) of at least 0.1 PHLU/LU, e.g. at least 0.5, particularly at least 2.

The variants of the invention may have the ability to hydrolyze intact phospholipid, as demonstrated by the PHLU method. They may have A₁ and/or A₂ activity, so they may be able to hydrolyze one or both fatty acyl groups in the phospholipid.

10 pH optimum

Many variants of the *Humicola lanuginosa* lipase have an alkaline pH optimum for lipase activity and an acid pH optimum for phospholipase activity (e.g. pH 9-10 for lipase and pH 4-6 for phospholipase). Such variants can be used at acid pH (e.g. in oil degumming, described later), as phospholipases with very low concomitant lipase activity.

However, some variants of the *Humicola lanuginosa* lipase which include the substitution G266D.E have pH optima for both lipase and phospholipase activities around pH 5-6. Such variants may be used at acid pH when both lipase and phospholipase activities are desired, e.g. in baking.

20 Thermostability

The thermostability of the variant can conveniently be evaluated by means of Differential Scanning Calorimetry (DSC). Depending on exact mutations, the variants of the invention generally have similar or slightly lower thermostability than the parent lipolytic enzyme.

The temperature at the top of the denaturation peak (T_d) of the lipase from *Humicola lanuginosa* when heated at 90 deg/hr at pH 5 is just above 70 °C (=T_d). T_d for the variants of the invention is generally 5-10 degrees lower

Use of variant

Depending on the substrate specificity, variants of the invention can be used, e.g., in filtration improvement, vegetable oil treatment, baking, detergents, or preparation of lysophospholipid.

Improvement of filtration

A variant with lysophospholipase activity can be used to improve the filterability of an aqueous solution or slurry of carbohydrate origin by treating it with the variant. This is particularly applicable to a solution or slurry containing a starch
5 hydrolysate, especially a wheat starch hydrolysate since this tends to be difficult to filter and to give cloudy filtrates. The treatment can be done in analogy with EP 219,269 (CPC International).

Vegetable oil treatment

A variant with phospholipase activity can be used in a process for reducing
10 the content of phospholipid in an edible oil, comprising treating the oil with the variant so as to hydrolyze a major part of the phospholipid, and separating an aqueous phase containing the hydrolyzed phospholipid from the oil. This process is applicable to the purification of any edible oil which contains phospholipid, e.g. vegetable oil such as soy bean oil, rape seed oil and sunflower oil. The treatment may be carried
15 out at acid pH, e.g. pH 3-5. Advantageously, a variant can be selected so as to have a high phospholipase activity and a low lipase activity at low pH, due to different pH optima of the two activities.

The process for oil treatment can be conducted according to principles known in the art, e.g. in analogy with US 5,264,367 (Metallgesellschaft, Röhm); K.
20 Dahlke & H. Buchold, INFORM, 6 (12), 1284-91 (1995); H. Buchold, Fat Sci. Technol., 95 (8), 300-304 (1993); JP-A 2-153997 (Showa Sangyo); or EP 654,527 (Metallgesellschaft, Röhm).

Miscellaneous uses of phospholipase

A variant with phospholipase activity can be used to prepare lysophosphol-
25 ipid (e.g. lyso-lecithin) by treating the corresponding phospholipid with the variant, e.g. as described in EP 870840, JP-A 10-42884, JP-A 4-135456 or JP-A 2-49593. The variant can also be used to make mayonnaise, e.g. as described in EP 628256, EP 398666 or EP 319064.

A variant with phospholipase activity may also be used in the processing of
30 dairy and other food products, e.g. as described in EP 567,662 (Nestlé), EP 426,211 (Unilever), EP 166,284 (Nestlé), JP-A 57-189638 (Yakult) or US 4,119,564 (Unilever).

The variant may be used leather treatment, as described in JP-A 7-177884 (Kao).

Baking

A variant with phospholipase and/or DGDGase activity can be used in the preparation of dough, bread and cakes, e.g. to increase dough stability and dough handling properties, or to improve the elasticity of the bread or cake.

5 Thus, the variant can be used in a process for making bread, comprising adding the variant to the ingredients of a dough, kneading the dough and baking the dough to make the bread. This can be done in analogy with US 4567,046 (Kyowa Hakko), JP-A 60-78529 (QP Corp.), JP-A 62-I 11629 (QP Corp.), JP-A 63-258528 (QP Corp.), EP 426211 (Unilever) or WO 99/53769 (Novo Nordisk).

10 It is particularly advantageous to use the variant together with an anti-staling endo-amylase and optionally also to add a phospholipid, to reduce-staling of the bread and particularly to improve softness of the bread in the first 24 hours after baking. The endo-amylase may be a maltogenic α -amylase (e.g. from *Bacillus sp.*, such as Novamyl[®] from Novo Nordisk) or a fungal or bacterial α -amylase, e.g. from *Aspergillus* or *Bacillus*, particularly *A. oryzae*, *B. licheniformis* or *B. amyloliquefaciens*.

15 In baking, the variant may have a low activity on short-chain or medium-chain (C_4 - C_8), e.g. corresponding to a SLU/LU ratio above 3. The use of such a variant may avoid or suppress the development of an undesired flavor due to the release of short-chain fatty acids. The variant may have activity on triglycerides and phospholipid as well as DGDG.

Cheese flavor

A variant with activity towards short-chain fatty acyl groups may be used to release free fatty acids (FFA) for flavor development in food products, e.g. in cheese ripening, e.g. as described in M. Hanson, ZFL, 41 (10), 664-666 (1990)).

25 Lipolytic enzyme variants with increased release of short chain fatty compared to long chain fatty acids from milk fat are useful in cheese production, e.g. for flavor enhancement or shortening of the ripening times for ripened cheeses, like cheddar or Parmesan. Another application for such lipolytic enzyme variants is for enzyme modified cheese (EMC) for use as flavoring for various food products including process cheese, dressing and snack.

30 Release of short chain fatty acids, like butyric acid, is essential for the development of cheese flavor, whereas release of long chain fatty acids, like oleic acid, give rise to off flavors. Lipolytic enzyme variants for cheese applications, including EMC, should have SLU/LU ratio of less than 0.5, e.g. less than 0.25, most preferable less than 0.1

Use in detergent

The variant may be used as a detergent additive, e.g. at a concentration (expressed as pure enzyme protein) of 0.001-10 (e.g. 0.01-1) mg per gram of detergent or 0.001-100 (e.g. 0.01-10) mg per liter of wash liquor.

5 In detergents, the variant may have a high activity on long-chain triglycerides (C_{16} - C_{20}) to improve the removal of fatty soiling. The variant may have phospholipase activity. The variant may have low activity towards short-chain (C_4 - C_8) fatty acids in triglycerides, e.g. corresponding to a SLU/LU ratio above 10. The use of such a variant may avoid or suppress the development of an undesired odor due to the release
10 of short-chain fatty acids.

Variants having both lipase and phospholipase activity at alkaline pH may be used in detergents.

Detergent composition

The detergent composition of the invention may for example be formulated
15 as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations. In a laundry detergent, the variant may be effective for the removal of fatty stains, for whiteness maintenance and for dingy
20 cleanup. A laundry detergent composition may be formulated as described in WO 97/04079, WO 97/07202, WO 97/41212, PCT/DK WO 98/08939 and WO 97/43375.

The detergent composition of the invention may particularly be formulated for hand or machine dishwashing operations. e.g. as described in GB 2,247,025 (Unilever) or WO 99101531 (Procter & Gamble). In a dishwashing composition, the variant
25 may be effective for removal of greasy/oily stains, for prevention of the staining /discoloration of the dishware and plastic components of the dishwasher by highly colored components and the avoidance of lime soap deposits on the dishware.

The detergent composition of the invention may be in any convenient form, e.g., a bar, a tablet, a powder, a granule, a paste or a liquid. A liquid detergent may
30 be aqueous, typically containing up to 70 % water and 0-30 % organic solvent, or non-aqueous.

The detergent composition comprises one or more surfactants, which may be non-ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic. The surfactants are typically present at a level of from 0.1% to 60% by weight, e.g.
35 0.5-40 %, such as 1-30 %, typically 1.5-20 %.

When included therein the detergent will usually contain from about 1% to about 40% of an anionic surfactant such as linear **alkylbenzenesulfonate**, **alpha-olefinsulfonate**, **alkyl sulfate** (fatty alcohol sulfate), **alcohol ethoxysulfate**, **secondary alkanesulfonate**, **alpha-sulfo fatty acid methyl ester**, **alkyl- or alkenylsuccinic acid** or soap.

When included therein the detergent will usually contain from about 0.2% to about 40% of a non-ionic surfactant such as **alcohol ethoxylate**, **nonyl-phenol ethoxylate**, **alkylpolyglycoside**, **alkyldimethylamine-oxide**, **ethoxylated fatty acid monoethanol-amide**, **fatty acid monoethanolamide**, **polyhydroxy alkyl fatty acid amide**, or **N-acyl N-alkyl derivatives of glucosamine** ("glucamides").

The invention also provides a detergent additive comprising the variant of the invention. The detergent additive as well as the detergent composition may comprise one or more other enzymes such as a **protease**, a **lipase**, a **cutinase**, an **amylase**, a **carbohydrase**, a **cellulase**, a **pectinase**, a **mannanase**, an **arabinase**, a **galactanase**, a **xylanase**, an **oxidase**, e.g., a **laccase**, and/or a **peroxidase**.

In general the properties of the chosen enzyme(s) should be compatible with the selected detergent, (i.e. **pH-optimum**, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.

Proteases: Suitable proteases include those of animal, vegetable or microbial origin. Microbial origin is preferred. Chemically modified or protein engineered mutants are included. The protease may be a **serine protease** or a **metallo protease**, e.g. an **alkaline microbial protease** or a **trypsin-like protease**. Examples of alkaline proteases are **subtilisins**, especially those derived from *Bacillus*, e.g., **subtilisin Novo**, **subtilisin Carlsberg**, **subtilisin 309**, **subtilisin 147** and **subtilisin 168** (described in WO 89106279). Examples of trypsin-like proteases are **trypsin** (e.g. of porcine or bovine origin) and the *Fusarium* protease described in WO 89/06270 and WO 94/25583.

Examples of useful proteases are the variants described in WO 92119729, WO 98/20115, WO 98/20116, and WO 98/34946, especially the variants with **substitutions** in one or more of the following positions: 27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 194, 206, 218, 222, 224, 235 and 274.

Specific commercially available **protease** enzymes include **Alcalase**®, **Savinase**®, **Primase**®, **Duralase**®, **Esperase**®, and **Kannase**® (Novo Nordisk A/S), **Maxatase**®, **Maxacal**®, **Maxapem**®, **Properase**®, **Purafect**®, **Purafect OXP**®, **FN2**™, and **FN3**™ (Genencor International Inc.).

Cellulases: Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases

include cellulases from the genera *Bacillus*, *Pseudomonas*, *Humicola*, *Fusarium*, *Thiefavia*, *Acremonium*, e.g. the fungal cellulases produced from *Humicola insolens*, *Myceliophthora thermophila* and *Fusarium oxysporum* disclosed in US 4,435,307, US 5648,263, US 5691,178, US 5776,757 and WO 89/09259.

Especially suitable cellulases are the alkaline or neutral cellulases having colour care benefits. Examples of such cellulases are cellulases described in EP 0 495 257, EP 0 531 372, WO 96/11262, WO 96129397, WO 98/08940. Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471, WO 98/12307 and PCT/DK98/00299.

Commercially available cellulases include Celluzyme[®], and Carezyme[®] (Novo Nordisk A/S), Clazinase[®], and Puradax HA[®] (Genencor International Inc.), and KAC-500(B)[®] (Kao Corporation).

Peroxidases/Oxidases: Suitable per-oxidases/oxidases include those of plant, bat-terial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from *Coprinus*, e.g. from *C. cinereus*, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98115257.

Commercially available peroxidases include Guardzyme[®] (Novo Nordisk A/S).

The detergent enzyme(s) may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes. A detergent additive of the invention, i.e. a separate additive or a combined additive, can be formulated e.g. as a granulate, a liquid, a slurry, etc. Specific detergent additive formulations are granulates, in particular non-dusting granulates, liquids, in particular stabilized liquids, or slurries.

Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molar weights of 1000 to 20000; ethoxylated nonyl-phenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591. Liquid enzyme preparations may, for in-stance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lac-

tic acid or boric acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP 238,216.

The detergent may contain 0-65 % of a detergent builder or **complexing** agent such as zeolite, diphosphate, triphosphate, phosphonate, carbonate, citrate, 5 nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst).

The detergent may comprise one or more polymers. Examples are carboxymethylcellulose, **poly(vinyl-pyrrolidone)**, poly(ethylene glycol), **poly(vinyl alcohol)**, 10 poly(vinylpyridine-N-oxide), **poly(vinylimidazole)**, polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

The detergent may contain a bleaching system which may comprise a H2O2 source such as perborate or percarbonate which may be combined with a **peracid-** 15 **forming bleach activator** such as tetraacetylenediamine or **nonanoyloxybenzenesulfonate**. Alternatively, the bleaching system may comprise peroxyacids of e.g. the amide, imide, or sulfone type.

The enzyme(s) of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e.g., a polyol such as propylene glycol or 20 glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as **4-formylphenyl boronic acid**, and the composition may be formulated as described in e.g. WO 92/19709 and WO 92/19708.

The detergent may also contain other conventional detergent ingredients 25 such as e.g. fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, **bactericides**, optical brighteners, hydrotropes, tarnish inhibitors, or perfumes.

It is at present contemplated that in the detergent compositions any enzyme, in particular the variant of the invention, may be added in an amount corresponding 30 to 0.01-100 mg of enzyme protein per liter of wash liquor, e.g. **0.05-5 mg** of enzyme protein per liter of wash liquor, in particular 0.1-1 mg of enzyme protein per liter of wash liquor.

The variant of the invention may additionally be incorporated in the detergent formulations disclosed in WO 97/07202 which is hereby incorporated as reference.

Methods for preparing enzyme variants

The enzyme variant of the invention can be prepared by methods known in the art, e.g. as described in WO 97/04079 (Novo Nordisk). The following describes methods for the cloning of enzyme-encoding DNA sequences, followed by
5 methods for generating mutations at specific sites within the enzyme-encoding sequence.

Cloning a DNA sequence encoding a enzyme

The DNA sequence encoding a parent enzyme may be isolated from any cell or microorganism producing the enzyme in question, using various methods well
10 known in the art. First, a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the enzyme to be studied. Then, if the amino acid sequence of the enzyme is known, labeled oligonucleotide probes may be synthesized and used to identify enzyme-encoding clones from a genomic library prepared from the organism in question. Al-
15 ternatively, a labeled oligonucleotide probe containing sequences homologous to another known enzyme gene could be used as a probe to identify enzyme-encoding clones, using hybridization and washing conditions of lower stringency.

Yet another method for identifying enzyme-encoding clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid,
20 transforming enzyme-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for enzyme (i.e. maltose), thereby allowing clones expressing the enzyme to be identified.

Alternatively, the DNA sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method
25 described S.L. Beaucage and M.H. Caruthers, (1981), Tetrahedron Letters 22, p. 1859-1869, or the method described by Matthes et al., (1984), EMBO J. 3, p. 801-805. In the phosphoroamidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.

30 Finally, the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate, the fragments corresponding to various parts of the entire DNA sequence), in accordance with standard techniques. The DNA sequence may also be prepared by polymerase
35 chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or R.K. Saiki et al., (1988). Science 239, 1988, pp. 487-491.

Site-directed mutagenesis

Once a enzyme-encoding **DNA** sequence has been isolated, and desirable sites for mutation identified, mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites. In a specific method, a single-stranded gap of DNA, the enzyme-encoding sequence, is created in a vector carrying the enzyme gene. Then the synthetic nucleotide, bearing the desired mutation, is annealed to a homologous portion of the single-stranded DNA. The remaining gap is then filled in with DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase. A specific example of this method is described in Motinaga et al., (1984), Biotechnology 2, p. 646-639. US 4,760,025 discloses the introduction of oligonucleotides encoding multiple mutations by performing minor alterations of the cassette. However, an even greater variety of mutations can be introduced at any one time by the Morinaga method, because a multitude of oligonucleotides, of various lengths, can be introduced.

Another method for introducing mutations into enzyme-encoding DNA sequences is described in Nelson and Long, (1989), Analytical Biochemistry 180, p. 147-151. It involves the 3-step generation of a PCR fragment containing the desired mutation introduced by using a chemically synthesized DNA strand as one of the primers in the PCR reactions. From the **PCR-generated** fragment, a DNA fragment carrying the mutation may be isolated by cleavage with restriction endonucleases and reinserted into an expression plasmid.

Further, Sierks. et al., (1989) "Site-directed mutagenesis at the active site Trp120 of *Aspergillus awamori* glucoamylase. Protein Eng., 2, 621-625; Sierks et al., (1990), "Catalytic mechanism of fungal glucoamylase as defined by mutagenesis of Asp176, Glu179 and Glu180 in the enzyme from *Aspergillus awamori*". Protein Eng. vol. 3, 193-198; also describes sitedirected mutagenesis in an *Aspergillus glucoamylase*.

Expression of enzyme variants

According to the invention, a DNA sequence encoding the variant produced by methods described above, or by any alternative methods known in the art, can be expressed, in enzyme form, using an expression vector which typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

Expression vector

The recombinant expression vector carrying the DNA sequence encoding a enzyme variant of the invention may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. The vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated. Examples of suitable expression vectors include pMT838.

Promoter

In the vector, the DNA sequence should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of the DNA sequence encoding a enzyme variant of the invention, especially in a bacterial host, are the promoter of the *lac* operon of *E.coli*, the *Streptomyces coelicolor* agarase gene *dagA* promoters, the promoters of the *Bacillus licheniformis* a-amylase gene (*amyL*), the promoters of the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the promoters of the *Bacillus amyloliquefaciens* a-amylase (*amyQ*), the promoters of the *Bacillus subtilis* *xylA* and *xylB* genes etc. For transcription in a fungal host, examples of useful promoters are those derived from the gene encoding *A. oryzae* TAKA amylase, the TPI (triose phosphate isomerase) promoter from *S. cerevisiae* (Alber et al. (1982), J. Mol. Appl. Genet 1, p. 419-434, *Rhizomucor miehei* aspartic proteinase, *A. niger* neutral a-amylase, *A. niger* acid stable a-amylase, *A. niger* glucoamylase, *Rhizomucor miehei* lipase, *A. oryzae* alkaline protease, *A. oryzae* triose phosphate isomerase or *A. nidulans* acetamidase.

Expression vector

The expression vector of the invention may also comprise a suitable transcription terminator and, in eukaryotes, polyadenylation sequences operably connected to the DNA sequence encoding the a-amylase variant of the invention. Termination and polyadenylation sequences may suitably be derived from the same sources as the promoter.

The vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.

The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the *dal* genes from *B. subtilis* or *B. licheniformis*, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracyclin resistance. Furthermore, the vector may comprise *Aspergillus* selection markers such as *amdS*, *argB*, *niaD* and *sC*, a marker giving rise to hygromycin resistance, or the selection may be accomplished by co-transformation, e.g. as described in WO 9107243.

The procedures used to ligate the DNA construct of the invention encoding an enzyme variant, the promoter, terminator and other elements, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989).

Host Cells

The cell of the invention, either comprising a DNA construct or an expression vector of the invention as defined above, is advantageously used as a host cell in the recombinant production of an enzyme variant of the invention. The cell may be transformed with the DNA construct of the invention encoding the variant, conveniently by integrating the DNA construct (in one or more copies) in the host chromosome. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e.g. by homologous or heterologous recombination. Alternatively, the cell may be transformed with an expression vector as described above in connection with the different types of host cells.

The cell of the invention may be a cell of a higher organism such as a mammal or an insect, but may be a microbial cell, e.g. a bacterial or a fungal (including yeast) cell.

Examples of suitable bacteria are Gram positive bacteria such as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus thuringiensis*, or *Streptomyces lividans* or *Streptomyces murinus*, or gramnegative bacteria such as *E.coli*. The transformation of the bacteria may, for instance, be effected by protoplast transformation or by using competent cells in a manner known *per se*.

The yeast organism may favorably be selected from a species of *Saccharomyces* or *Schizosaccharomyces*, e.g. *Saccharomyces cerevisiae*.

The host cell may also **be a** filamentous fungus e.g. a strain belonging to a species of *Aspergillus*, such as *Aspergillus oryzae* or *Aspergillus niger*, or a strain of *Fusarium*, such as a strain of *Fusarium oxysporum*, *Fusarium graminearum* (in the perfect state named *Gibberella zeae*, previously *Sphaetia zeae*,
5 synonym with *Gibberella roseum* and *Gibberella roseum f. sp. cerealis*), or *Fusarium sulphureum* (in the perfect state named *Gibberella purpuris*, synonym with *Fusarium trichothecioides*, *Fusarium bactridioides*, *Fusarium sambucium*, *Fusarium roseum*, and *Fusarium roseum var. graminearum*), *Fusarium cerealis* (synonym with *Fusarium crockwellense*), or *Fusarium venenatum*.

10 In a specific embodiment of the invention the host cell is a protease deficient of protease minus strain.

This may for instance be the protease deficient strain *Aspergillus oryzae* JaL 125 having the alkaline protease gene named "alp" deleted. This strain is described in WO 97/35956 (Novo Nordisk).

15 Filamentous fungi cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known per se. The use of *Aspergillus* as a host micro-organism is described in EP 238 023 (Novo Nordisk A/S), the contents of which are hereby incorporated by reference.

20 Method of producing the enzyme variant of the invention

The enzyme variant of the invention may be produced by a method comprising cultivating a host cell under conditions conducive to the production of the variant and recovering the variant from the cells and/or culture medium.

25 The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in question and obtaining expression of the enzyme variant of the invention. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. as described in catalogues of the American Type Culture Collection).

30 The enzyme variant secreted from the host cells may conveniently be recovered from the culture medium by well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, followed by the use of chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

Expression of variant in plants

The present invention also relates to a transgenic plant, plant part or plant cell which has been transformed with a DNA sequence encoding the variant of the invention so as to express and produce this enzyme in recoverable quantities.

5 The enzyme may be recovered from the plant or plant part. Alternatively, the plant or plant part containing the recombinant enzyme may be used as such.

The transgenic plant can be dicotyledonous or monocotyledonous, for short a dicot or a **monocot**. Examples of **monocot** plants are grasses, such as meadow grass (blue grass, *Poa*), forage grass such as *festuca*, *lolium*, temperate grass, such as *Agrostis*, and cereals, e.g. wheat, oats, rye, barley, rice, sorghum and maize (corn).

Examples of dicot plants are tobacco, legumes, such as lupins, potato, sugar beet, pea, bean and soybean, and cruciferous (family *Brassicaceae*), such as cauliflower, oil seed rape and the closely related model organism *Arabidopsis thaliana*.

15 Examples of plant parts are stem, callus, leaves, root, fruits, seeds, and tubers. In the present context, also specific plant tissues, such as chloroplast, apoplast, mitochondria, vacuole, peroxisomes and cytoplasm are considered to be a plant part. Furthermore, any plant cell, whatever the tissue origin, is considered to be a plant part.

20 Also included within the scope of the invention are the progeny of such plants, plant parts and plant cells.

The transgenic plant or plant cell expressing the variant of the invention may be constructed in accordance with methods known in the art. In short the plant or plant cell is constructed by incorporating one or more expression constructs encoding the variant of the invention into the plant host genome and propagating the resulting modified plant or plant cell into a transgenic plant or plant cell.

25 Conveniently, the expression construct is a DNA construct which comprises a gene encoding the variant of the invention in operable association with appropriate regulatory sequences required for expression of the gene in the plant or plant part of choice. Furthermore, the expression construct may comprise a selectable marker useful for identifying host cells into which the expression construct has been integrated and DNA sequences necessary for introduction of the construct into the plant in question (the latter depends on the DNA introduction method to be used).

35 The choice of regulatory sequences, such as promoter and terminator sequences and optionally signal or transit sequences is determined, eg on the basis of when, where and how the enzyme is desired to be expressed. For instance, the expression of the gene encoding the variant of the invention may be constitutive or in-

ducible, or may be developmental, stage or tissue specific, and the gene product may be targeted to a specific tissue or plant part such as seeds or leaves. Regulatory sequences are eg described by Tague et al, Plant, Phys., 86, 506, 1988.

5 For constitutive expression the **35S-CaMV** promoter may be used (Franck et al., 1980. Cell 21: 285-294). Organ-specific promoters may eg be a promoter from storage sink tissues such as seeds, potato tubers, and fruits (Edwards & Coruzzi, 1990. Annu. Rev. Genet. 24: **275-303**), or from metabolic sink tissues such as meristems (Ito et al., 1994. Plant Mol. Biol. 24: **863-878**), a seed specific promoter such as the glutelin, prolamin, globulin or albumin promoter from rice (Wu et al., Plant and Cell Physiology Vol. 39, No. 8 pp. 885-889 (1998)), a *Vicia faba* promoter from the legumin B4 and the unknown seed protein gene from *Vicia faba* described by Conrad U. et al, Journal of Plant Physiology Vol. 152, No. 6 pp. 708-711 (1998), a promoter from a seed oil body protein (Chen et al., Plant and cell physiology vol. 39, No. 9 pp. 15 935-941 (1998)), the storage protein **napA** promoter from *Brassica napus*, or any other seed specific promoter known in the art, eg as described in WO 91/14772. Furthermore, the promoter may be a leaf specific promoter such as the rbcS promoter from rice or tomato (Kyoizuka et al., Plant Physiology Vol. 102, No. 3 pp. 991-1000 (1993)), the chlorella virus adenine methyltransferase gene promoter (Mittra, A. and 20 Higgins, DW, Plant Molecular Biology Vol. 26, No. 1 pp. 85-93 (1994)), or the **aldP** gene promoter from rice (Kagaya et al., Molecular and General Genetics Vol. 248, No. 6 pp. 668-674 (1995)), or a wound inducible promoter such as the potato pin2 promoter (Xu et al, Plant Molecular Biology Vol. 22, No. 4 pp. 573-588 (1993)).

A promoter enhancer element may be used to achieve higher expression of 25 the enzyme in the plant. For instance, the promoter enhancer element may be an intron which is placed between the promoter and the nucleotide sequence encoding the enzyme. For instance, Xu et al. *op cit* disclose the use of the first intron of the rice **actin 1** gene to enhance expression.

The selectable marker gene and any other parts of the expression construct 30 may be chosen from those available in the art.

The DNA construct is incorporated into the plant genome according to conventional techniques known in the art, including *Agrobacterium*-mediated transformation, virus-mediated transformation, micro injection, particle bombardment, biolistic transformation, and electroporation (Gasser et al, Science, 244, 1293; Potrykus, 35 Bio/Techn. 8. 535, 1990; Shimamoto et al, Nature, 338, 274, 1989).

Presently, *Agrobacterium tumefaciens* mediated gene transfer is the method of choice for generating transgenic dicots (for review Hooykas & Schilperoort, 1992.

Plant Mol. Biol. 19: 15-38), however it can also be used for transforming monocots, although other transformation methods are generally used for these plants. Presently, the method of choice for generating transgenic monocots is particle bombardment (microscopic gold or tungsten particles coated with the transforming DNA) of embryonic calli or developing embryos (Christou, 1992. Plant J. 2: 275-281; Shimamoto, 1994. Curr. Opin. Biotechnol. 5: 158-162; Vasil et al., 1992. Bio/Technology 10: 667-674). An alternative method for transformation of monocots is based on protoplast transformation as described by Omirulleh S, et al., Plant Molecular biology Vol. 21, No. 3 pp. 415-428 (1993).

Following transformation, the transformants having incorporated the expression construct are selected and regenerated into whole plants according to methods well-known in the art.

MATERIALS AND METHODS

Lipase activity on tributyrin (LU)

A substrate for lipase is prepared by emulsifying tributyrin (glycerin tributyrate) using gum Arabic as emulsifier. The hydrolysis of tributyrin at 30 °C at pH 7 is followed in a pH-stat titration experiment. One unit of lipase activity (1 LU) equals the amount of enzyme capable of releasing 1 μ mol butyric acid/min at the standard conditions.

Lipase activity on triolein (SLU)

The lipolytic activity may be determined using olive oil as substrate.

In this SLU method, the lipase activity is measured at 30 °C and pH 9 with a stabilized olive oil emulsion (Sigma catalog No. 800-I) as the substrate, in a 5 mM Tris buffer containing 40 mM NaCl and 5 mM calcium chloride. 2.5 ml of the substrate is mixed with 12.5 ml buffer, the pH is adjusted to 9, 0.5 ml of diluted lipase sample is added, and the amount of oleic acid formed is followed by titration with a pH stat.

One SLU is the amount of lipase which liberates 1 mole of titratable oleic acid per minute under these conditions.

Phospholipase activity

The following assay methods were used for qualitative or quantitative determination of phospholipase activity.

Phospholipase activity (PHLU)

Phospholipase activity (PHLU) is measured as the release of free fatty acids from lecithin. 50 μ l 4% L-alpha- phosphatidylcholine (plant lecithin from Avanti), 4 % Triton X-100, 5 mM CaCl_2 in 50 mM HEPES, pH 7 is added 50 μ l enzyme solution diluted to an appropriate concentration in 50 mM HEPES, pH 7. The samples are incubated for 10 min at 30 °C and the reaction stopped at 95 °C for 5 min prior to centrifugation (5 min at 7000 rpm). Free fatty acids are determined using the NEFA C kit from Wako Chemicals GmbH; 25 μ l reaction mixture is added 250 μ l Reagent A and incubated 10 min at 37 °C. Then 500 μ l Reagent B is added and the sample is incubated again, 10 min at 37 °C. The absorption at 550 nm is measured using an HP 8452A diode array spectrophotometer. Samples are run in at least in duplicates. Substrate and enzyme blinds (preheated enzyme samples (10 min at 95 °C) + substrate) are included. Oleic acid is used as a fatty acid standard. 1 PHLU equals the amount of enzyme capable of releasing 1 μ mol of free fatty acid/min at these conditions.

Phospholipase activity (LEU)

Lecithin is hydrolyzed under constant pH and temperature, and the phospholipase activity is determined as the rate of titrant (0.1N NaOH) consumption during neutralization of the liberated fatty acid.

The substrate is soy lecithin (L-a-Phosphotidyl-Choline), and the conditions are pH 8.00, 40.0°C, reaction time 2 min. The unit is defined relative to a standard.

Phospholipase monolayer assay

On a thoroughly purified surface of a buffer solution (either 10 mM Glycin, pH 9.0 or 10 mM NaOAc, pH 5.0; 1 mM CaCl_2 , 25°C) a monolayer of Di-Decanoyl-Phosphatidyl Choline (DDPC) is spread from a chloroform solution. After relaxation of the monolayer (evaporation of chloroform) the surface pressure is adjusted to 15 mN/m, corresponding to a mean molecular area of DDPC of approx. 63 Å²/molec. A solution containing approximately 60 μ g (micro gram) enzyme is injected through the monolayer into the subphase of the re-action compartment (cylinder with surface area 2230 mm² and reaction volume 56570 mm³) in the "zero-order trough". Enzymatic activity is manifested through the speed of a mobile barrier compressing the monolayer in order to maintain constant surface pressure as insoluble substrate molecules are hydrolyzed into more water soluble reaction products. Having verified that the aqueous solubility of the reaction products (capric acid and MDPC) are considerably higher than for DDPC the number of DDPC-molecules hydrolyzed per min-

ute by the enzyme is estimated from the mean molecular area (MMA) of DDPC. The results are calculated on basis of average barrier speed over the first 5 minutes of hydrolysis.

The result is considered positive for phospholipase if the barrier moves at
5 more than 2 mm/min.

Plate assay 1

A) 50 ml 2% agarose in purified water is melted/stirred for 5 minutes and cooled to 60 - 63°C.

B) 50 ml 2% plant L-alpha-Phosphatidylcholine 95% in 0,2M NaOAc, 10 mM
10 CaCl₂, pH 5,5 at 60°C in 30 min. is blended in 15 sec. with ultrathorax.

Equal volumes of 2% agarose and 2% Lecithin (A and B) are mixed, and an equal volume of 1 % Triton X-100 is added to this mixture. 250 µl 4 mg/ml crystal violet in purified water is added as indicator. The mixture is poured into appropriate petri dishes (e.g. 30 ml in 14cm Ø dish), and appropriate holes are made in the agar (3-5
15 mm) for application of enzyme solution.

The enzyme sample is diluted to a concentration corresponding to OD₂₈₀ = 0.5 and 10 microliter is applied into holes in the agarose/lecithin-matrix. Plates are incubated at 30°C and reaction zones in the plates are identified after approx. 4-5 hours and/or after approx. 20 hours incubation. The *Humicola lanuginosa* lipase is
20 used as a control, and the presence of a larger clearing zone than the control is taken as a positive result for phospholipase activity.

In a variation of this assay, the addition of Triton X-100 is omitted.

Plate assay 2

10 g agarose is melted in 550 ml H₂O by boiling in a microwave oven. After
25 cooling to 60-70°C the following ingredients are added:

250 ml of a 0.4 M Citrate buffer (pH 4.5 or pH 7.1)

200 ml 3% lecithin (from **Avanti**) in 2% Triton-X 100

2 ml 2% crystal violet

30 ml of the mixture is poured into 14 cm Ø petri dishes.

30 The plates are incubated after application of enzyme samples, and the results are interpreted as for Plate assay 1.

Digalactosyl diglyceride hydrolyzing (DGDGase) activityMonolayer assay 1

On a thoroughly purified surface of a buffer solution (10 mM NaOAc, pH 5.5; 1 mM CaCl₂, 25°C; 10 mM beta-cyclodextrin (Sigma C-4767)) a monolayer of DGDG (Sigma (D4651)) is spread from a chloroform solution. After relaxation of the monolayer (evaporation of chloroform) the surface pressure is adjusted to 15 mN/m. A solution containing approximately 60 µg (micro gram) enzyme is injected through the monolayer into the subphase of the re-action compartment (cylinder with surface area 2230 mm² and reaction volume 56570 mm³) in the "zero-order trough". Enzymatic activity is manifested through increased speed of a mobile barrier compressing the monolayer in order to maintain constant surface pressure as insoluble substrate molecules are hydrolyzed into more water soluble reaction products (in presence of beta cyclodextrin).

The result is considered positive for DGDGase if the barrier moves at more than 1 mm/min.

Monolayer 2

On a thoroughly purified surface of a buffer solution (approx. 75 ml, 10 mM NaOAc, pH 5.5; 1 mM CaCl₂, 25°C; 10 mM beta-cyclodextrin (Sigma C-4767)) a monolayer of DGDG (Sigma (D4651)) is spread from a chloroform solution to a surface pressure of about 30 mN/m. After relaxation of the monolayer (evaporation of chloroform) a solution containing approximately 30 µg (micro gram) purified enzyme is injected through the monolayer into the 75 ml subphase while surface pressure is measured continuously. Enzymatic activity is manifested through increased rate of decrease in surface pressure as DGDG is hydrolyzed into water soluble reaction products (in presence of beta cyclodextrin).

The result is considered positive for DGDGase if maximal drop in surface pressure ($d\pi/dt$) after addition of enzyme exceeds -0.5 mN/min. A number of variants of Lipolase were tested and found to have DGDGase activity, whereas the parent enzyme (Lipolase) only had very limited activity ($d\pi/dt > -0.5$ mN/min.) .

Yeast Strain

Saccharomyces cerevisiae YNG318: MATa leu2-D2 ura3-52 his4-539 pep4-D1[cir+], described in WO 97/04079 and WO 97/07205.

Transformation of yeast strain

The DNA fragments and the opened vectors are mixed and transformed into the yeast *Saccharomyces cerevisiae* YNG318 by standard methods.

5 Vector for yeast transformation

pJSO026 (*S. cerevisiae* expression plasmid) is described in WO 97/07205 and in J.S.Okkel, (1996) "A URA3-promoter deletion in a pYES vector increases the expression level of a fungal lipase in *Saccharomyces cerevisiae*. Recombinant DNA Biotechnology III: The Integration of Biological and Engineering Sciences, vol. 782 of the Annals of the New York Academy of Sciences). It is derived from pYES 2.0 by replacing the inducible GAL1 -promoter of pYES 2.0 with the constitutively expressed TPI (triose phosphate isomerase)-promoter from *Saccharomyces cerevisiae* (Albert and Karwasaki, (1982), J. Mol. Appl Genet., 1, 419-434), and deleting a part of the URA3 promoter.

15 Site-directed mutagenesis

For the construction of variants of a *H. lanuginosa* lipolytic enzyme the commercial kit, Chameleon double-stranded, sitedirected mutagenesis kit can be used according to the manufacturer's instructions.

The gene encoding the lipolytic enzyme in question is inserted into the plasmid pHD414. In accordance with the manufacturer's instructions the *Sca*I site of the Ampicillin gene of pHD414 is changed to a *Mlu*I site by use of the following primer:

Primer 3: AGAAATCGGGTATCCTTTCAG.

The pHD414 vector comprising the lipolytic gene in question is then used as a template for DNA polymerase and oligos 7258 and 7770.

25 7258: 5'p gaa tga ctt ggt tga cgc gtc acc agt cac 3'

(Thus changing the *Sca*I site-found in the ampicillin resistance gene and used for cutting to a *Mlu*I site).

Primer no. 7770 was used as the selection primer.

7770: 5'p tct agc cca gaa tac tgg atc aaa tc 3' (Changes the *Sca*I site found in the *H. lanuginosa* lipase gene without changing the amino acid sequence).

30 The desired mutation (e.g. in the N-terminal of the lipolytic gene or the introduction of a cystein residue) is introduced into the lipolytic gene in question by addition of an appropriate oligos comprising the desired mutation.

PCR reactions are performed according to the manufacturer's recommendations.

35 tions.

Screening method

The yeast libraries are spread on cellulose filters on SC-ura agar plates and incubated for 3-4 days at 30°C.

- 5 The filters are then transferred to the lecithin plates and incubated at 37°C for 2-6 hours. Yeast cells harboring active phospholipases will develop white clearing zones around the colonies. The positive variants can then be further purified and tested.
-

Media

SC-ura medium

Yeast Nitrogen (without amino acids)	7.5 g
Succinic acid	11.3 g
NaOH	6.8 g
Casaminoacid (without vitamins)	5.6 g
Tryptophan	0.1 g
Agar, Merck	20 g
Distilled water	ad 1000 ml

Autoclaved for 20 minutes at 121 °C.

- 5 From a sterile stock solution of 5% Threonine 4 ml is added to a volume of 900 ml together with 100 ml of a sterile 20% glucose.

EXAMPLES

Example 1: Construction of variants with the backbone from *Humicola lanuginosa* lipase and C-terminal from *Fusarium oxysporum* phospholipase by PCR reaction

- 10 The following variants were used as templates for the backbone from the *Humicola lanuginosa* lipase: E1A +G91A +D96W +E99K +Q249R and SPIRR +G91A +D96W +E99K +Q249R. The parent lipase was used for generating a fragment in the C-terminal without Q249R. The template for the C-terminal phospholipase was the *Fusarium oxysporum* phospholipase, cloned in the same vector as the variants of *Humicola lanuginosa* lipase.

PCR reaction 1: 4244 (SEQ ID NO: 1) as 5' primer and H7 (SEQ ID NO: 6) as 3' primer and one of the two templates mentioned above.

- PCR reaction 2: FOL14 (SEQ ID NO: 3) as 5' primer and FOL15 (SEQ ID NO: 4) as 3' primer and *Humicola lanuginosa* lipase as template (no mutation in pos 249)

PCR reaction 3: FOL16 (SEQ ID NO: 5) as 5' primer and AP (SEQ ID NO: 2) as 3' primer and F.o. phospholipase as template

- 25 A PCR reaction 4 was made to create the connection between the *Humicola lanuginosa* lipase variant and the C-terminal from the phospholipase by using FOL14

(SEQ ID NO: 3) as 5' primer and AP (SEQ ID NO: 2) as 3' primer and PCR reaction 2 and 3 as template.

The final PCR was made with 4244 (SEQ ID NO: 1) as 5' primer and KBoj14 (SEQ ID NO: 7) as 3' primer and PCR re-action 1 and 4 as template (by using *Humicola lanuginosa* lipase as template in reaction 2 a possibility to omit the mutation in position 249 was created).

The final PCR fragment was used in an in vivo recombination in yeast together with pJSO026 cut with the restriction enzymes. **SmaI(or BamHI)** and XbaI (to remove the coding region and at the same time create an overlap of about 75 bp in each end to make a recombination event possible). This final treatment was also used in the following examples.

Primer FOL14 (SEQ ID NO: 3) and primer 15116 are mixed oligoes to give the possibility to bind both with *Humicola lanuginosa* lipase and phospholipase templates and at the same time give possibilities for introducing the amino acids from both templates in the different positions. For some of the positions new amino acids could be introduced as well.

Primer FOL14 (SEQ ID NO: 3)

Position 205 in the *H. lanuginosa* lipase: 75% R, 25% S

Primer FOL15 (SEQ ID NO: 4) /FOL16 (SEQ ID NO: 5)

Position 256 in the *H. lanuginosa* lipase: 50% P, 50% A

Position 260 in the *H. lanuginosa* lipase: 25% R, 12.5% Q, 12.5% H, 12.5% C, 12.5% Y, 12.5% W, 12.5% stop.

The sequences of the resulting variants were determined, and were found to correspond to *Humicola lanuginosa* lipase with the following alterations. Alterations in parentheses are uncertain.

E1A, G91A, D96W, E99K, P256A, W260H, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271G, 272G, 273F, (274S)

E1A, G91A, D96W, E99K, E239C, Q249R, P256A, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271G, 272G, 273F, (274S)

E1A, G91A, D96W, E99K, N248T, Q249R, W260Q, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271G, 272G, 273F, (274S)

SPIRR, G91A, D96W, E99K, W260C, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271G, 272, G273F, (274S)

SPIRR, G91A, D96W, E99K, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271 G, 272G, 273F, (274S)

E1A, G91A, D96W, E99K, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271G, 272G, 273F, (274S)

Example 2: Production of truncated sequences

Variants were made with stop after amino acid 269, 270, 271, 272, (273 and 274)

The following PCR reactions were made with the following template: E1A, G91A, D96W, E99K, P256A, W260H, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271G, 272G, 273F, (2748).

Reaction 1: 5' primer 4244 (SEQ ID NO: 1) and 3' primer KBoj36 (stop after 269)

Reaction 2: 5' primer 4244 (SEQ ID NO: 1) and 3' primer KBoj37 (stop after 270)

Reaction 3: 5' primer 4244 (SEQ ID NO: 1) and 3' primer KBoj38 (stop after 271)

Reaction 4: 5' primer 4244 (SEQ ID NO: 1) and 3' primer KBoj39 (stop after 272)

The sequences of the resulting variants were determined, and were found to correspond to *Humicola lanuginosa* lipase with the following alterations:

E1A, G91A, D96W, E99K, P256A, W260H, G263Q, L264A, I265T, G266D, T267A, L269N

E1A, G91A, D96W, E99K, P256A, W260H, G263Q, L264A, I265T, G266D, T267A, L269N, 270A

E1 A, G91A, D96W, E99K, P256A, W260H, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271G

E1 A, G91A, D96W, E99K, P256A, W260H, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271 G, 272G

Example 3: Removal of mutations in the lid region

G91A or E99K can be removed without losing the phospholipase activity. The sequences of the resulting variants were determined, and were found to correspond to *Humicola lanuginosa* lipase with the following alterations:

E1A, G91A, D96W, P256A, W260H, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271 G, 272G, 273F, (274S)

SPIRR, D96W, E99K, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271G, 272G, 273F, (2748)

SPIRR, G91A, D96W, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271G, 272G, 273F, (2748)

E1 A, G91A, D96W, P256A, W260H, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271G, 272G, 273F, (2748)

Example 4: Doping in the C-terminal region of Humicola lanuginosa lipase to introduce phospholipase activity

Three different libraries were constructed with possibilities for mutations in position 256 and position 263-269. At the same time possibilities for extension of the C-terminal with either 1, 2, 3 or 4 amino acids were included.

Doping, the wt sequences are underlined:

256: P 94, A 3, T 3

263: · · · · ·, G 87 E 4.8, A 3.8, R 3.6, Q 0.2, P 0.2

264: L 87, P 4.8, Q 3.8, V 3.6, A 0.2, E 0.2

265: · · · · ·, I 85 T 5.6, L 2.2, S 1.6, N 1.5, F 1.4, R 0.4, K 0.4 A,P 0.1, G,D,C,H,Y 0.03, Q,E 0.01, stop 0.016

266: G 86, D 5.9, R 2, S 1.7, C 1.6, A 0.9, V 0.9, E 0.7, W 0.2, H,Y 0.1, I,L,T,F,P 0.02, Q,K 0.01, stop 0.014

267: · · · · · A 6.6, S 1.9, R 0.9, N 0.9, I 0.9, K 0.9, M 0.9, P 0.9, P 0.9, G,V 0.14, D,E 0.07, L 0.03, C,Q,H,F,W,Y 0.01, stop 0.01

268: C 91, S 1.9, R 1.0, G 1.0, F 0.9, Y 0.9, L 0.04, A,N,D,H,I,P,T,V 0.01, stop 2.8

269: L 92, stop 8 (KBoj 32 (SEQ ID NO: 8) and KBoj33)/ N 86, K 2.7, D 1.8, H 1.8, I 1.8, S 1.8, T 1.9, Y 1.8, R 0.1, Q,M,E 0.06, A,C,G,L,F,P,V 0.04, stop 0.06(KBoj34)

270: stop 100 (KBoj33)/A 44, P 44, S 1.9, T 1.8, R 1.5, L 1.5, G 1.4, V 1.4, D 0.7, Q 0.7, E 0.7, H 0.7, N,C,I,K,M,F,W,Y 0.03, stop 0.03 (KBoj 32 (SEQ ID NO: 8) and KBoj 34)

271: G 72, R 4.5, V 3.2, E 3.0, C 2.9, A 1.6, S 1.2, D 1.0, L 0.5, I,K,Y 0.15, Q,T 0.08, N,P 0.05, stop 9.2

272: G 72, R 4.5, V 3.2, E 3.0, C 2.9, A 1.6, S 1.2, D 1.0, L 0.5, I,K,Y 0.15, Q,T 0.08, N,P 0.05, stop 9.2

273: F 74, L 11, S 2.8, I 2.7, V 2.7, Y 2.5, C 2.5, A,R,T 0.1, N,D,H 0.08, Q,E,K 0.01, stop 0.5

274 STOP

Library A: PCR reaction with 4244 (SEQ ID NO: 1) as 5' primer and KBoj 33 as 3' primer and E1A +G91A +D96W +E99K +Q249R or E1A +G225R as template. Variants from this library will be without extension.

Library B: PCR reaction with 4244 (SEQ ID NO: 1) as 5' primer and KBoj 32 (SEQ ID NO: 8) as 3' primer and E1A +G91A +D96W +E99K +Q249R or E1A +G225R as template. Variants from this library will most probably contain a C-terminal extension but can contain stop codons before the extension.

Library C: PCR reaction with 4244 (SEQ ID NO: 1) as 5' primer and KBoj 34 as 3' primer and E1A +G91A +D96W +E99K +Q249R or E1A +G225R as template. Variants from this library will most probably contain mutations in position 269 and a C-terminal extension but can contain stop codons before the extension.

The following variants were obtained:

Library A:

E1A +G91A +D96W +E99K +Q249R +G266D

Library B:

10 E1A +G91A +D96W +E99K +(R232L) +Q249R +G266S +270A
 E1A +G91A +D96W +E99K +Q249R +G266S +270D +271G
 E1A +G91A +D96W +E99K +Q249R +L264G +I265G +G266F +T267stop
 E1A +G91A +D96W +E99K +Q249R +G266A +270P +271G
 E1A +G91A +D96W +E99K +Q249R +L264P +I265F +L269stop

15 Library C:

E1A +G91A +D96W +E99K +Q249R +G263E +G266D +L269N +270P
 +271V +272G +273F
 E1A +G91A +D96W +E99K +Q249R +G263A +G266S +L269N +270A
 +271G +272R +273F
 20 E1A +G91A +D96W +E99K +Q249R +L264P -G266 +L269I +270P +271R
 +272G +273F
 E1A +G91A +D96W +E99K +Q249R +G266D +L269S +270A +271G +272G
 +273F
 E1A +D27G +G91A +D96W +E99K +Q249R +G266S +L269N +270A +271G
 25 +272G +273F
 E1A +G91A +D96W +E99K +Q249R +G266D +L269N +270A
 E1A +G91A +D96W +E99K +Q249R +L264P +L267Q +L269N
 E1A +G91A +D96W +E99K +Q249R +G263R +I265L +L269N +270P

Example 5: For some of the above variants, the pH optimum for lipase and phospholipase was determined by using the LU and PHLU methods at various pH values. The results showed that the pH optimum phospholipase activity was in the range 4-6. The optimum for lipase activity varied from about pH 6 to about pH 10.

8 variants listed in Example 5 were analyzed for phospholipase activity by the mono layer assay described above at pH 5 and 9. The results showed that all the variants have phospholipase activity at pH 5 and 9, whereas the parent lipase

(*Humicola lanuginosa* lipase) showed no activity at pH 5 or 9. Depending on the variant, the activity at pH 5 was higher or lower than at pH 9.

A prior-art variant of *Humicola lanuginosa* lipase was found to have no phospholipase activity at pH 5: SPIRR +N94K +F95L +D96H +N101S +F181L +D234Y +I252L +P256T +G263A +L264Q.

Example 5: Variants of *Humicola* lipase with phospholipase activity

Variants of the parent lipase from *Humicola lanuginosa* were prepared and tested for phospholipase activity as described above. The following variants were found to have phospholipase activity, where as the parent had no phospholipase activity by the same method.

E1A, G91A, D96W, E99K, P256A, W260H, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271G, 272G, 273F, (2748)
SPIRR, G91A, D96W, E99K, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271 G, 272G, 273F, (274S)
E1A, G91A, D96W, P256A, W260H, G263Q, L264A, I265T, G266D, T267A, L269N, 270A, 271 G, 272G, 273F, (2748)
E1A, G91A, D96W, E99K, P256A, W260H, G263Q, L264A, I265T, G266D, T267A, L269N
E1A, G91A, D96W, E99K, Q249R, G266S, 270D, 271G
E1 A, G91A, D96W, E99K, Q249R, G266D
E1A, G91A, D96W, E99K, Q249R, G266A, 270P, 271G
G266D
EI SPPCGRRP +E99N +E239C +Q249R +G266D
EI SPPCGRRP +E239C +Q249R +G266D
EI SPPCGRRP +L93K +E99K +E239C +Q249R +G266D
E1SPPCGRRP +E99K +E239C +Q249R +G266D
G266A
G266W
G266V
G263Q +L264A +I265T +G266D +T267A
G263F +L264A +G266S +T267E
EI SPPCGRRP +E239C +Q249R +G263Q +L264A +I265T +G266D +T267A
G266S

G266L
G263A +G266A
G263A +G266Y
EI SPPCGRRP +E239C +Q249R +G266A
EI SPPCGRRP +E239C +Q249R +G266S
EI SPPCGRRP +E239C +Q249R +G263F +L264A +G266S +T267E
D62A + G266A
D62A + G266S
D96S + G266A
D96S+ G266S
D96S+ G266R
D96S+ G266W
D96S+ G266V
EI SPPCGRRP + G91A+ D96W+ E239C+ Q249R+ G266D
EI SPPCGRRP + G91A+ D96W+ E239C+ Q249R+ G266S
EI SPPCGRRP + G91A+ D96W+ E239C+ Q249R+ G263E+ G266S+ 270A
EI SPPCGRRP + G91A+ D96W+ E239C+ Q249R+ L264P+ G266S
E1SPPCGRRP + G91A+ D96W+ E239C+ Q249R+ P256T+ G266D
EI SPPCGRRP + G91A+ D96W+ E239C+ Q249R+ G266C+ T267P+ L269stop
G263D +L264I +I265N +G266E +T267GS
E219G +L264I +I265N +G266T +T267GL
E I A + G91A+ D96W+ E99K+ P256A+ W260H+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N+ 270A+ 271 G+ 272G+ 273F (+274S)
E I A + G91A+ D96W+ E99K+ E239C+ Q249R+ P256A+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N+ 270A+ 271 G+ 2726 +273F (+274S)
E1A+ G91A+ D96W+ E99K+ N248T+ Q249R+ W260Q+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N+ 270A+ 271G+ 272G+ 273F (+274S)
SPIRR+ G91A+ D96W+ E99K+ W260C+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N+ 270A+ 271G+ 272+ G273F (+274S)
SPIRR+ G91A+ D96W+ E99K+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N+ 270A+ 271 G+ 272G+ 273F (+274S)
E1A+ G91A+ D96W+ E99K+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N+

270A+ 271G+ 272G+ 273F (+274S)
E1A+ G91A+ D96W+ E99K+ P256A+ W260H+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N+ 270A+ 271G +272G +273F (+274S)
SPIRR+ D96W+ E99K+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N+ 270A+ 271 G+ 272G+ 273F (+274S)
SPIRR+ G91A+ D96W+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N+ 270A+ 271 G+ 272G+ 273F (+274S)
E1A+ G91A+ D96W+ E99K+ P256A+ W260H+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N
E1A+ G91A+ D96W+ E99K+ Q249R+ G263E+ G266D+ L269N+ 270P+ 271V+ 272G+ 273F
EI A+ G91A+ D96W+ E99K+ Q249R+ G263A+ G266S+ L269N+ 270A+ 271G+ 272R+ 273F
E1A+ G91A+ D96W+ E99K+ Q249R+ L264P+ Δ266+ L269I+ 270P+ 271R+ 272G+ 273F
E1A+ G91A+ D96W+ E99K+ Q249R+ L264C+ I265N+ G266P+ T267stop
E1A+ G91A+ D96W+ E99K (+R232L)+ Q249R+ G266S+ 270A
EIA+ G91A+ D96W+ E99K+ Q249R+ G266S+ 270D+ 271G
E1A+ G91A+ D96W+ E99K+ Q249R+ L264F+ Δ266+ 270A+ 271G+ 272G+ 273F
E1A+ G91A+ D96W+ E99K+ Q249R+ L264G+ I265G+ G266F+ T267stop
E1A+ G91A+ D96W+ E99K+ Q249R+ L264stop
E I A + G91A+ D96W+ E99K+ P256A+ W260H+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N+ 270A+ 271 G
E1A+ G91A+ D96W+ E99K+ P256A+ W260H+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N+ 270A+ 271 G+ 2726
E1A+ G91A+ D96W+ E99K+ Q249R+ G266D
E1A+ G91A+ D96W+ E99K+ Q249R+ G266D
E1A+ G91A+ D96W+ E99K+ Q249R+ G266A+ 270P+ 271G
E1A+ G91A+ D96W+ E99K+ Q249R+ L264P+ I265F+ L269stop
E1A+ G91A+ D96W+ E99K+ Q249R+ G266D+ L269S+ 270A+ 271G+ 272G+ 273F
E1A+ G91A+ D96W+ E99K+ Q249R+ G266D+ L269N+ 270A
EI A+ G91A+ D96W+ E99K+ Q249R+ G266S+ L269N+ 270A+ 271G+ 272G+ 273F
E1A+ G91A+ D96W+ E99K+ Q249R+ L264P+ L267Q+ L269N

E1A+ G91A+ D96W+ E99K+ Q249R+ G263R+ I265L+ L269N+ 270P
E1A+ D96W+ E99K+ P256A+ W260H+ G263Q+ L264A+ I265T+ G266D+ T267A+ L269N+ 270A+ 271.G+ 272G+ 273F (+274S)
E1A+ G225R+ G266D
E1A+ G225R+ G263A+ I265V+ G266S
E1A+ G225R+ G263A+ T267A
E1SPPCGRRP+ D96S+ E239C+ Q249R+ I252M+ L264Q+ G266D
E1SPPCGRRP+ G91A+ D96W+ E239C+ Q249R+ G266D
E1SPPCGRRP+ D96S+ E239C+ Q249R+ G266D
E1SPPCGRRP+ D96S+ E239C+ Q249R+ G266C+ L267A
E1A+ G91A+ D96W+ E99K+ Q249R+ G266A
E1A+ D96M+ G106S+ G225R+ G266D
E1A+ D96Q+ G106S+ G225R+ G266S
E1A+ D96F+ G225R+ G266S
E1A+ D96C+ G225R+ G266T
E1A+ D96H+ G106S+ G225R+ G266S
SPIRR+ D96S+ G266D
SPIRR+ D96R+ G106S+ G266D
SPIRR+ D96I+ G106S+ G266S
SPIRR+ D96W+ K237R+ G266S
SPIRR+ G266A
SPIRR+ D96S+ G106S+ G225R+ G266D
SPIRR+ D96Q+ G106S+ G225R+ G266A
SPIRR+ D96Y+ G106S+ G225R+ G266N
SPIRR+ D96C+ G106S+ G225R+ G266T
SPIRR+ D96H+ T186I+ G225R+ G266S
E1SPRRP+ G91A+ D96W+ E239C+ Q249R+ G266D
E1 SPRRP+ G91A+ D96W+ E239C+ Q249R+ G266S
E1SPRRP+ G91A+ D96W+ E239C+ Q249R+ G263E+ G266S+ 270A
E1 SPRRP+ G91A+ D96W+ E239C+ Q249R+ L264P+ G266S

E1SPPRRP+ G91A+ D96W+ E239C+ Q249R+ P256T+ G266D
E1SPPRRP+ G91A+ D96W+ E239C+ Q249R+ G266C+ T267P+ L269stop
E1A+ G91A+ D96W+ E99K+ Q249R+ G266S+ T267S
EI SPPCGRRP+ G91A+ D96W+ E239C+ Q249R+ P256T+ G266S
EI SPPCGRRP+ E239C+ Q249R+ P256T+ G266S+ T267A
EI SPPCGRRP+ E239C+ Q249R+ G266D
EI SPPCGRRP+ G91A+ D96W+ E239C+ Q249R+ G266D
EI SPPRRP+ D96S+ E239C+ Q249R+ G266D
L259S
G266D
G91A +D96W +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A+ 271 G+ 272G+ 273F (+274S)
G266E
G263A +G266A
EI SPCRPRP +E239C +Q249R +G266A
E1 SPCRPRP +E239C +Q249R +G266S
D96S + G266A
D96S + G266S
D96S + G266W
EISPPCGRRP +D96S +E239C +Q249R +G263D +L264I +I265N +G266E +T267GS
EISPPCGRRP +D96S +E239C +Q249R +L264I +I265N +G266T +T267GL
D96F +G266A
D96F +G266S
EI SPPCGRRP +E99N +E239C +Q249R +G266A
EI SPPCGRRP + D96S +E239C +Q249R +G266A
EI SPPCGRRP + D96S +E239C +Q249R +G266S
E1SPPCGRRP + D96S +E239C +Q249R +G263F +L264A +G266S +T267E
V60G +D62A +S83T +R84K +D96W +G266D
V60G +D62A +S83T +D96W +G266D
V60G +D62A +S83T +D96W +G266W

L259I
L259N
D96W +G263Q +L264A +I265T +G266D +T267A

In the table above, (+274S) indicates that the presence of this amino acid residue at the C-terminal is uncertain. For one such variant, it was found that only a minor fraction contained this residue

Several of the above variants had a higher ratio of phospholipase (PHLU) to lipase (LU) than a prior-art enzyme from *F. oxysporum* known to have both lipase and phospholipase activity.

For some of the above variants, the pH optimum for lipase and phospholipase was determined by using the LU and PHLU methods at various pH values. The results showed that the pH optimum phospholipase activity was in the range 4-6. The optimum for lipase activity varied from about pH 6 to about pH 10.

8 variants listed in Example 5 were analyzed for phospholipase activity by the mono layer assay described above at pH 5 and 9. The results showed that all the variants have phospholipase activity at pH 5 and 9, whereas the parent lipase (*Humicola lanuginosa* lipase) showed no activity at pH 5 or 9. Depending on the variant, the activity at pH 5 was higher or lower than at pH 9.

A prior-art variant of *Humicola lanuginosa* lipase was found to have no phospholipase activity at pH 5: SPIRR +N94K +F95L +D96H +N101S +F181L +D234Y +I252L +P256T +G263A +L264Q.

The following variants of the parent lipase from *Humicola lanuginosa* may also have phospholipase activity:

D62A +S83T +D96W +G266S
G91A +D96W +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96L +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96N +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96A +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96E +E99K +G263Q +L264A +I265T +G266D +T267A +L269N

+270A +271G +272G +273F +274S
G91A +D96S +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96R +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96G +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96Q +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96F +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96W +E99K +G263Q +L264A +I265T +G266S +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96F +E99K +G263Q +L264A +I265T +G266S +T267A +L269N +270A +271G +272G +273F +274S +
R84W +G91A +D96W +E99K +G263Q +L264A +I265T +G266S +T267A +L269N +270A +271G +272G +273F +274S
R84W +G91A +D96F +E99K +G263Q +L264A +I265T +G266S +T267A +L269N +270A +271G +272G +273F +274S +
R84W +G91A +D96F +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96F +G263Q +L264A +I265T +G266S +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96W +G263Q +L264A +I265T +G266S +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96F +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96W +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S

Example 6: Variants of *Rhizomucor* lipase with phospholipase activity

The following two variants of the parent lipase from *Rhizomucor miehei* were prepared and tested for phospholipase activity as described above. The variants were found to have phospholipase activity, where as the parent had no phospholipase activity by the same method.

G266N

G266V

Example 7: Variants of *Humicola* lipase with increased specificity for long-chain fatty acids

5 Variants of the parent lipase from *Humicola lanuginosa* were prepared and tested for their hydrolytic activity on two triglyceride substrates with different chain length: tributyrin (C_{4:0}) and triolein (C_{18:1}). The tests were done at pH 9 by the LU and SLU methods described above. The following variants were found to have a higher ratio of triolein activity to tributyrin activity than the parent enzyme (*Humicola lanuginosa* lipase):

EISPIRPRP +G91A +D96N +E99K +Q249R
E1SPCRPRP+ S83T+ N94K+ D96L+ E239C+ Q249R
G266D
E1SPIRPRP +D62A +E99K +Q249R
EI SPIRPRP +D62G +E99K +Q249R
EI SPIRPRP +D62V +E99K +Q249R
EI SPIRPRP +R84W +E99K +Q249R
EI SPIRPRP +R84K +E99K +Q249R
EI SPIRPRP + K98D +E99K +Q249R
E1SPIRPRP + E99K +Q249R + 270PGLPFKRV
E1SPPCGRRP + E99N +N101S +T231K +R232G +D234G +E239C +Q249R
EISPIRPRP +E99K +Q249R + 270PWPARLGRL
L93K +D96G
G91A +D96W +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A+ 271G+ 272G+ 273F (+274S)
E1SPCRPRP +V60G +E99N +S119G +R209P +E239C +Q249R
G266A
G266E
G266V
G263Q +L264A +I265T +G266D +T267A
G266L
G263A +G266A
EI SPCRPRP +E239C +Q249R +G266A

EI SPCRPRP +E239C +Q249R +G266S
D96S + G266A
D96S + G266S
D96S + G266W
L264I +I265N +G266T +T267GL
EI SPPCGRRP +D96S +E239C +Q249R +L264I +I265N +G266T +T267GL
D96F +G266A
D96F +G266S
EISPPCGRRP +E99N +E239C +Q249R +G266A
EISPPCGRRP + D96S +E239C +Q249R +G266A
E1SPPCGRRP + D96S +E239C +Q249R +G266S
D62A + S83T
EI SPPCGRRP +K98D +E99N +E239C +Q249R
T231R +N233R +270CP
EISPPCGRRP +E99N +E239C +Q249R +270MD
EISPPCGRRP + D62A +S83T +E99N +E239C +Q249R
D62A +S83T + G91A +E99K +T231R +N233R +Q249R
V60G +D62A +S83T +R84K +D96W +G266D
L259N
L259R
L259M
L259Q
SPPCGRRP(-E) +R84W +E99N +N101S +E239C +Q249R
R84W +G91A +E99K +T231R +N233R +Q249R
Y21I
Y21V
SPIRPRP(-E) +R84L +E99K +Q249R
Y21C
SPIRPRP(-E) +D62 +E99K +Q249R
D96W +G263Q +L264A +I265T +G266D +T267A +L269N +A270 +G271 +G272 +F273

+S274.
G91A +D96W +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271 G +272G +273F +274S
The following variants of the parent lipase from <i>Humicola lanuginosa</i> may also have an increased specificity for long-chain fatty acids:
SPIRPRP(-E) +V60R +D62V +L93K +E99K +Q249R
SPIRPRP(-E) +D62V +E99K +Q249R
SPIRPRP(-E) +E99K +Q249R +P256D
SPIRPRP(-E) +D62V +E99K +Q249R +P256D
SPIRPRP(-E) +D62V +E99K +Q249R +P256S
G91A +D96W +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271 G +272G +273F +274S
G91A +D96L +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96N +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271 G +272G +273F +274S
G91A +D96A +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96E +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271 G +272G +273F +274S
G91A +D96S +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96R +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96G +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271 G +272G +273F +274S
G91A +D96Q +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96F +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
G91A +D96W +E99K +G263Q +L264A +I265T +G266S +T267A +L269N +270A +271 G +272G +273F +274S
G91A +D96F +E99K +G263Q +L264A +I265T +G266S +T267A +L269N +270A +271 G +272G +273F +274S
R84W +G91A +D96W +E99K +G263Q +L264A +I265T +G266S +T267A +L269N

+270A +271G +272G +273F +274S
R84W +G91A +D96F +E99K +G263Q +L264A +I265T +G266S +T267A +L269N +270A +271G +272G +273F +274S
R84W +G91A +D96F +E99K +G263Q +L264A +I265T +G266D +T267A +L269N +270A +271G +272G +273F +274S
SPPCGRRP(-E) +V60G +D62E +S83T +R84K +E99N +N101S +E239C +Q249R
V60G +D62E +S83T +R84K +G91A +E99K +T231R +N233R +Q249R

Example 8: Variants of *Fusarium* lipase with increased specificity for long-chain fatty acids

Variants of the parent lipase from *Fusarium oxysporum* were prepared and tested as in the previous example. The following variants were found to have a higher ratio of triolein activity to tributyrin activity than the parent enzyme:

Y23S

Y260L

The following variants of the parent lipase from *Fusarium oxysporum* may also have an increased specificity for long-chain fatty acids:

R80H +S82T

S82T +A129T

Example 9: Variants of *Rhizomucor* lipase with increased specificity for long-chain fatty acids

The following variants of the parent lipase from *Rhizomucor miehei* may have an increased specificity for long-chain fatty acids:

Y260W

Y28L

Y28C +H217N

Example 10: Variants of *Humicola* lipase with increased specificity for short-chain fatty acids

Variants of the parent lipase from *Humicola lanuginosa* were prepared and tested as in the previous example. The following variants were found to have a higher ratio of tributyrin activity to triolein activity (a lower SLU/LU ratio) than the parent enzyme:

SPIRPRP(-E) +E99K +R195Q +R209E +Q249R
N101R +R195Q +R209E +L259S +Y261D
N101R +R195Q +R209E +L259S
N101R +L259S +Y261D
N101R +L259S
Y261 D
L259S
SPIRPRP(-E) +E99K +N101 R +Q249R
G263D +L264I +I265N +G266E +T267GS
Y261I
D234R
Y261 K

The following variants of the parent lipase from *Humicola lanuginosa* may also have a higher ratio of tributyrin activity to triolein activity:

N101R,R195Q,R209E,L259S,Y261D
N101R,R195Q,R209E,L259S
N101R,L259S,Y261D
N101R,L259S

Example 11: Variants of *Fusarium* lipase with increased specificity for short-chain fatty acids

5 Variants of the parent lipase from *Fusarium oxysporum* were prepared and tested as in the previous example. The following variants were found to have a higher ratio of tributyrin activity to triolein activity than the parent enzyme:

Y23W
Y260D
10 Y260R
Y260C
Y260N

Example 12: Variants of *Rhizomucor* lipase with increased specificity for short-chain fatty acids

15 The following variants of the parent lipase from *Rhizomucor miehei* may have an increased specificity for short-chain fatty acids:

Y260C

Y260G

Y260V

Example 13: Variants of *Humicola* lipase with DGDGase activity

- 5 Variants of the parent lipase from *Humicola* *ianuginosa* were prepared, and the hydrolytic activity towards DGDG (di-galactosyl-di-glyceride) was determined as described above. The following variants were found to have DGDGase activity, whereas the parent lipase gave a negative result.

D96W +G263Q +L264A +I265T +G266D +T267A

G263Q +L264A +I265T +G266D +T267A

D96W +G263Q +L264A +I265T +G266D +T267A +L269N +270AGGFS

G91A +D96W +E99K +G263Q +L264A +I265T +G266D +T267A +L269N
+270AGGFS

D96F +G266S

Example 14: Variants of *Humicola* lipase with increased pH optimum

- 10 Variants of the parent lipase from *Humicola* *ianuginosa* were prepared, and the lipase activity was measured by the LU method at pH 7 and 9. The following variants were found to have a higher ratio of activity at pH 9 to activity at pH 7 than the parent lipase:

R84L

15 R84W

Y21I

Y21V

Y261 I

Example 15: Variants of *Humicola* lipase with decreased pH optimum

- 20 Variants of the parent lipase from *Humicola* *ianuginosa* were prepared, and the lipase activity was measured by the LU method at pH 7 and 9. The following variants were found to have a lower ratio of activity at pH 9 to activity at pH 7 than the parent lipase:

Y261 D

25 G266D/E

Y261 W

Example 16: Use of *Humicola* lipase variants in degumming of vegetable oil

Rapeseed oil was treated with two variants of the lipase from *Humicola lanuginosa*, essentially as described in Example 6 of WO 98/18912 (Novo Nordisk).

5 One variant was tested at an enzyme dosage of 0.6 mg of enzyme protein per kg of oil. Results of tests at various pH and temperatures showed optimum performance at pH 5.7, 35-45°C, where a final P content of 4 ppm was reached. A separate experiment at 45°C, pH 6 showed that a final P content of 4 ppm could be reached at an enzyme dosage as low as 0.15 mg/kg.

10 A similar experiment with another *Humicola lanuginosa* lipase variant showed optimum performance at 40°C, pH 5.0-5.5. The enzyme dosage was 0.3 mg/kg.

A degumming experiment was made with a third *Humicola lanuginosa* lipase variant, using rape seed oil at 45°C, pH 5, 1.8 mg enzyme/kg oil. For comparison, a
15 similar experiment was made with the parent lipase (*Humicola lanuginosa* lipase) at 18 mg/kg. The results showed that good degumming (<10 ppm residual P content) was obtained in 3.4 hours with the variant.

The parent lipase (*Humicola lanuginosa* lipase) was found to have very little degumming effect, even at 10 times higher enzyme dosage.

20 **Example 17: Use of lipase variants in baking**

A variant of the lipase from *Humicola lanuginosa* was evaluated in baking tests as follows.

Doughs were prepared from Meneba flour according to the European straight dough method (ABF-SP-1201.01) with 40 ppm of ascorbic acid. Various
25 combinations of additives at the following dosages were used: the lipase variant at 0, 0.25, 0.5 or 1.5 mg/kg; phospholipid (lecithin) at 0 or 10 g/kg; and endo-amylase at 0 or 750 MANU/kg.

The endo-amylase was maltogenic amylase from *B. stearothermophilus* (tradenname Novamyl®). One MANU (Maltogenic Amylase Novo Unit) is defined as the
30 amount of enzyme required to release one μmol of maltose per minute at a concentration of 10 mg of maltotriose substrate per ml of 0.1 M citrate buffer, pH 5.0 at 37°C for 30 minutes.

After baking, the loaves were cooled, and the loaf volume, crumb firmness and softness were evaluated after approximately 2 hours. The evaluation was re-
35 peated after 1, 3 and 7 days storage at 22°C wrapped in double plastic bags.

Firmness of crumb was measured using a texture analyzer TA-XT2 from Stable Micro Systems (probe diameter 40 mm).

Softness in gram was measured as the force needed to press a probe 6.25 mm into a crumb of a 25 mm thick slice of bread (25 % penetration).

5 The results showed that the addition of 1.5 mg of the variant increased the loaf volume. The results for firmness and elasticity show that the variant gives significantly softer crumb and significantly better elasticity from day 0 to day 7.

Example 18: Use of lipase variants for dough stability in baking

A variant of the *Humicola lanuginosa* lipase was evaluated in a baking trial to
10 evaluate its tolerance towards extended proofing of the dough.

Doughs were prepared from Pelikan flour according to the European straight dough method (347-SP-1217) with 30 ppm ascorbic acid, fungal α -amylase (10 FAU of Fungamyl), and pentosanase (100 FXU of Pentopan Mono). Dosages of 0.2, 0.4, and 0.6 mg enzyme protein/kg flour of the variant were compared with 1000 LU of
15 the parent lipase.

The doughs were made into rolls. Half of the rolls were proofed for 45 minutes (normal proofing) and the other half for 70 minutes (over proofing).

After baking the bread was cooled, and the volume and the standing of the rolls were evaluated after approximately 2 hours. The standing is a measure of the
20 shape of the rolls and is defined as the height of 10 rolls divided by the width of 10 rolls, which means that nice round loaves have a high standing value, whereas flat rolls have a low standing value.

The results showed that at normal proofing time the volume of 0.4 and 0.6 mg of the variant were better than that of the parent lipase, and the standing of the
25 rolls were better for the variant at all dosages than for the parent lipase. When the rolls were over proofed, both volume and standing was better for the variant at all dosages than for the parent lipase.

Example 19: Effect of lipase variants on off-odor development

The development of off-odor from lipases with different chain-length specificity was evaluated in whole milk. The developed butyric acid/sour odor was evaluated
30 by sniffing the samples after heating.

25 ml whole milk was placed in 100 ml blue cap flasks (with caps) in a 32°C water bath. Of each of the lipases listed below, 0.2 mg enzyme protein per litre milk was added to the flasks. The temperature was raised to 45°C, and evaluation took
35 place after 15 and 105 minutes.

The lipases tested were *Humicola lanuginosa* lipase and variants thereof. For each lipase, the chain-length specificity is expressed as the ratio of activities on triolein (SLU) and tributyrin (LU).

Three persons evaluated the samples and agreed on the ranking shown below

- + Detectable smell
- ++ Clear and characteristic butyric acid and/or sour odor
- +++ Strong butyric acid and/or sour odor

Three variants of *Humicola lanuginosa* lipase having a higher SLU/LU ratio than *Humicola lanuginosa* lipase were found to have less malodour than the parent lipase.

Example 20: Effect of lipase variants on malodour on textile after washing

Soilina:

Cotton textile was soiled with a dairy product as described here. 50 mg of butter was applied over an area of approximately 30 cm² in an even spot. The soiled textile was aged for 24 hours at ambient conditions.

Washing procedure:

Washing of the soiled textile was done in a Terg-0-tometer using a commercial detergent(5 g/l) with and without lipase(1250 and 5000 LU/l). The washing was done at 30°C for 20 min at 100 rpm. After washing the swatches were left overnight to dry at ambient conditions.

Sensory analysis:

Next day, the malodour was assessed by a sensory panel consisting of at least 10 trained assessors. Samples were kept in tight glass jars and left at least 30 minutes between every evaluation for accumulation of malodour. Swatches were taken out and the malodour assessed on the textile. The butyric acid malodour was scored according to the scale below. As a reference the sample washed without lipase was used.

- 0. Fainter smell than reference
- 1. Same as reference
- 2. Slightly stronger than reference
- 3. Definitely stronger than reference
- 4. Stronger than 3.

Variants of *Humicola lanuginosa* lipase with an increased ratio of triolein/tributyrin activities (increased SLU/LU ratio) were found to give a fainter smell from butter stains than the parent enzyme (*Humicola lanuginosa* lipase). A separate washing experiment showed that the variants, like the parent enzyme, were effective in the removal of lard stains.

Alternative methods

The intensity of butyric acid from dairy stains on fabric can also be evaluated by instrumental analysis:

1. By Head Space Gas Chromatography, or
2. By extraction of the odours from fabric followed by Gas Chromatography

Example 21: Effect of lipase variants on odour of bread baked with butter

Six variants of the lipase from *Humicola lanuginosa* were prepared and were evaluated in bread baked by the European straight dough procedure (347-SP-1217) with addition of 3% butter. 0.2 mg enzyme protein/kg flour was used for each of the variants.

The chain-length specificity of the variants was also determined by measuring the triolein/tributyrin activity ratio (SLU/LU described above). The parent lipase from *Humicola lanuginosa* and a prior-art lipase with phospholipase activity from *Fusarium oxysporum* were also tested for comparison.

The results are summarized below:

- + detectable smell
- ++ clear and characteristic butyric acid and/or sour odour
- +++ strong butyric acid and/or sour odour

25

30

	SLU/LU	Rating
Variants of the	2.7	(+)
	3	no effect
	7	no effect

invention	28	no effect
	70	no effect
Parent lipase	1.2	++
Prior-art lipase	1.1	+++
Control (no lipase)	-	no effect

The results indicate that that lipase variants with a **SLU/LU** ratio at 3 or above (i.e. a high specificity for long-chain fatty acids) give no unpleasant odour in bread baking even with butter in the recipe.

CLAIMS

1. A method of producing a lipolytic enzyme variant comprising:
 - a) selecting a substrate and an ester bond of interest,
 - b) selecting a parent lipolytic enzyme having an alcohol binding site having a
5 glycerol part with an **sn2** position,
 - c) in the parent lipolytic enzyme selecting at least one amino acid residue which comprises at least **one atom** within 10 Å of the C atom at the sn2 position of the glycerol part of a substrate triglyceride in a three-dimensional structure of the parent lipolytic enzyme and the substrate,
 - 10 d) making alterations each of which is an insertion, a deletion or a substitution of the amino acid residue,
 - e) optionally, making alterations each of which is an insertion, a deletion or a substitution of an amino acid residue at one or more positions other than b),
 - f) preparing the variant resulting from steps b-d,
 - 15 g) testing the activity of the variant on the selected ester bond,
 - h) selecting a variant having an altered activity on the selected ester bond, and
 - i) producing the selected variant.

2. A method of producing a lipolytic enzyme variant comprising:
 - 20 a) selecting a substrate and an ester bond of interest,
 - b) selecting a parent lipolytic enzyme having a structure comprising a catalytic triad consisting of an active Ser, an active Asp and an active His residue,
 - c) in the parent lipolytic enzyme selecting at least one amino acid residue
25 comprising at least one atom belonging to a set E defined by the following steps:
 - i) aligning the structure of the lipolytic enzyme with *Rhizomucor miehei* lipase structure 4TGL comprising a catalytic triad and an inhibitor phosphorus atom (4TGL-inhP), so as to minimize the sum of squares

of deviation between atoms of the catalytic triads of the two structures,

ii) defining a set A consisting of atoms of the lipolytic enzyme inside a sphere of radius 18 Å with center at 4TGL-inhP,

iii) forming a first plane defined by 4TGL-inhP, the Ca atom of the active Ser residue of the parent lipolytic enzyme, and the Cα atom of the active Asp residue of the parent lipolytic enzyme and defining a set B as a subset of set A consisting of atoms on the same side of the first plane as the Ca atom of the active His residue of the parent lipolytic enzyme,

iv) forming a second plane defined by 4TGL-inhP, the Cα atom of the active Ser residue of the parent lipolytic enzyme, and the Cα atom of the active His residue of the parent lipolytic enzyme and defining a set C as a subset of set A consisting of atoms on the opposite side of the second plane from the Cα atom of the active Asp residue of the parent lipolytic enzyme,

v) forming a set D consisting of atoms belonging to the union of sets B and C, and having a solvent accessibility of 15 or higher, and

vi) forming set E consisting of amino acid residues in the structure which comprise an atom belonging to set D or an atom belonging to the union of sets B and C and located less than 3.5 Å from an atom belonging to set D,

d) making alterations each of which is an insertion, a deletion or a substitution of the selected amino acid residues,

e) optionally, making alterations each of which is an insertion, a deletion or a substitution of an amino acid residue at one or more positions other than d),

f) preparing the variant resulting from steps d) - f), and

g) testing the activity of the variant on the selected ester bond,

h) selecting a variant having an altered activity on the selected ester bond, and

i) producing the selected variant.

3. A method of producing a lipolytic *enzyme* variant comprising:
- a) selecting a substrate and an ester bond of interest,
 - b) selecting a parent lipolytic enzyme having an active site comprising an active His residue,
 - 5 c) in the amino acid sequence of the parent lipolytic enzyme selecting at least one amino acid residue at the C-terminal side of the active His residue,
 - d) making alterations each of which is an insertion, a deletion or a substitution of the amino acid residue,
 - e) optionally, making alterations each of which is an insertion, a deletion or a substitution of an amino acid residue at one or more positions other than b),
 - 10 f) preparing the variant resulting from steps b-d,
 - g) testing the activity of the variant on the selected ester bond,
 - h) selecting a variant having an altered activity on the selected ester bond, and
 - 15 i) producing the selected variant.
4. A method of producing a lipolytic enzyme variant comprising:
- a) selecting a substrate and an ester bond of interest,
 - b) selecting a parent lipolytic enzyme,
 - c) selecting at least one amino acid residue among 10 amino acid residues
 - 20 at the C-terminal,
 - d) making alterations each of which is an insertion, a deletion or a substitution of the selected amino acid residues,
 - e) optionally, making alterations each of which is an insertion, a deletion or a substitution of an amino acid residue at one or more positions other than c),
 - 25 f) preparing the variant resulting from steps c) - e),
 - g) testing the activity of the variant on the selected ester bond,
 - h) selecting a variant having an altered activity on the selected ester bond, and
 - i) producing the selected variant.
- 30 5. A method of producing a lipolytic enzyme variant comprising:

- a) selecting a substrate and an ester bond of interest,
- b) selecting a parent lipolytic enzyme having a lid,
- c) selecting at least one amino acid residue in the lid,
- d) making alterations each of which is an insertion, a deletion or a substitution of the selected amino acid residues,
- e) optionally, making alterations each of which is an insertion, a deletion or a substitution of an amino acid residue at one or more positions other than c),
- f) preparing the variant resulting from steps c) - e),
- g) testing the activity of the variant on the selected ester bond,
- h) selecting a variant having an altered activity on the selected ester bond, and
- i) producing the selected variant.

6. The method of any of claims 1-5 wherein the lipolytic enzyme is native to an eukaryote, preferably to a fungus, and most preferably belongs to the *Humicola* family or the *Zygomycetes* family.

7. A method of producing a lipolytic enzyme variant comprising:

- a) selecting a substrate and an ester bond of interest,
- b) selecting a parent lipolytic enzyme from the *Humicola* family or the *Zygomycetes* family,
- c) selecting at least one amino acid residue corresponding to any of amino acids 20-25, 56-64, 81-85 and 255-269 in the *Humicola lanuginosa* lipase
- d) making alterations each of which is an insertion, a deletion or a substitution of the amino acid residue,
- e) optionally, making alterations each of which is an insertion, a deletion or a substitution of an amino acid residue at one or more positions other than c),
- f) preparing the variant resulting from steps b-e,
- g) testing the activity of the variant on the ester bond in the substrate, and
- h) selecting a variant having an altered activity on the ester bond.

8. The method of claim 7 wherein the parent lipolytic enzyme is the lipase of *Humicola lanuginosa* strain DSM 4109.
9. The method of any of claims 1-8 wherein the altered activity is a lower activity towards a C₄-C₈ acyl bond in a triglyceride, or a lower ratio of activity towards a C₄-C₈ acyl bond in a triglyceride and a C₁₆-C₂₀ acyl bond in a triglyceride.
10. The method of claim 9 wherein the parent lipolytic enzyme belongs to the *Humicola* family or the *Zygomycetes* family, preferably the lipase of *Humicola lanuginosa* strain DSM 4109, and the selected amino acid residues comprise an amino acid corresponding to Y21, E56, D57, V60, G61, D62, R81, S83, R84, L259, Y261 or G266 in the *Humicola lanuginosa* lipase.
11. The method of any of claims 1-8 wherein the altered activity is a lower activity towards a C₁₆-C₂₀ acyl bond in a triglyceride, or a lower ratio of activity towards a C₁₆-C₂₀ acyl bond in a triglyceride and a C₄-C₈ acyl bond in a triglyceride.
12. The method of any of claims 1-8 wherein the altered activity is a higher phospholipase activity.
13. The method of claim 12 wherein the parent lipolytic enzyme has a phospholipase activity below 50 PHLU/mg and/or a ratio of phospholipase activity to lipase activity below 0,1 PHLU/LU.
14. The method of claim 12 or 13 wherein the parent lipolytic enzyme belongs to the *Humicola* family or the *Zygomycetes* family, preferably the lipase of *Humicola lanuginosa* strain DSM 4109, and the selected amino acid residues comprise an amino acid corresponding to R81, R84, S85, or 263-267 (e.g. G266 or T267) in the *Humicola lanuginosa* lipase.
15. The method of any of claims 12-14 wherein the alterations comprise insertion of a peptide extension at the C-terminal, preferably comprising 1-5 amino acid residues, the first preferably being A, P or D, the second (if present) preferably being V, G or

R, the third (if present) preferably being V, G or R, the fourth (if present) preferably being F, and the fifth (if present) preferably being S.

16. The method of any of claims 1-8 wherein the altered activity is a higher hydrolytic activity on a digalactosyl-diglyceride.

5 17. The method of claim 16 wherein the parent lipolytic enzyme belongs to the *Humicola* family or the Zygomycetes family, preferably the lipase of *Humicola lanuginosa* strain DSM 4109, and the selected amino acid residues comprise an amino acid corresponding to 21, 23, 26, 57, 62, 81, 83, 84, 85, 266, 267 or 269 in the *Humicola lanuginosa* lipase.

10 18. A method of preparing a lipolytic enzyme variant for use in baking, which method comprises:

- a) selecting a parent lipolytic enzyme,
- b) making at least one alteration which is an insertion, a deletion or a substitution of an amino acid residue in the lipolytic enzyme to obtain a lipolytic enzyme variant,
- 15 c) screening for a lipolytic enzyme variant which compared to the parent lipolytic enzyme has:
 - i) a higher ratio selectivity for long-chain fatty acyl groups,
 - ii) a higher activity on digalactosyl diglyceride, and
 - 20 iii) a higher phospholipase activity, and
- d) preparing the lipolytic enzyme variant.

19. The method of claim 18 wherein the parent lipolytic enzyme and the amino acid to be altered are selected as defined in any of claims 1-8.

20 20. A method of preparing a lipolytic enzyme variant for use in baking, which method comprises

- a) subjecting a DNA sequence encoding a lipolytic enzyme to random mutagenesis,

- b) expressing the mutated DNA sequence obtained in step (a) in a host cell, and
- c) screening for host cells expressing a lipolytic enzyme variant which compared to the parent lipolytic enzyme has:
- 5 i) a higher ratio selectivity for long-chain fatty acyl groups,
- ii) a higher activity on digalactosyl diglyceride, and
- iii) a higher phospholipase activity, and
- d) preparing the lipolytic enzyme expressed by the host cells.
21. A lipolytic enzyme which is a variant of a parent lipolytic enzyme having an alcohol binding site having a glycerol part with an sn2 position, which variant:
- 10 a) comprises an alteration which is an insertion, a deletion or a substitution of an amino acid residue, at a position which in a three-dimensional structure of the parent lipolytic enzyme and a substrate is within 10 Å of the C atom at the sn2 position of the glycerol part of a substrate triglyceride, and
- 15 b) has an altered activity on an ester bond in the substrate.
22. A lipolytic enzyme which is a variant of a parent lipolytic enzyme having a lid, which variant:
- a) comprises an alteration which is an insertion, a deletion or a substitution of an amino acid residue in the lid,
- 20 b) has an altered activity on an ester bond in the substrate.
23. A lipolytic enzyme which is a variant of a parent lipolytic enzyme having an active site comprising an active His residue, which variant:
- a) comprises an alteration which is an insertion, a deletion or a substitution of at least one amino acid residue at the C-terminal side of the active His residue,
- 25 b) has an altered activity on an ester bond in a substrate.
24. A lipolytic enzyme which is a variant of a parent lipolytic enzyme, which variant:
-

- a) comprises an alteration which is an insertion, a deletion or a substitution of at least one amino acid within 10 amino acid residues of the C-terminal,
- b) has an altered activity on an ester bond in a substrate.

5 25. The lipolytic enzyme of any of claims 21-24 wherein the parent lipolytic enzyme is native to an eukaryote, preferably to a fungus, and most preferably belongs to the *Zygomycetes* family.

26. The lipolytic enzyme of claim 25 wherein the parent lipolytic enzyme belongs to the *Humicola* family or the *Zygomycetes* family, preferably the lipase of *Humicola lanuginosa* strain DSM 4109.

10

27. A lipolytic enzyme which:

- a) is a polypeptide having an amino acid sequence which has at least 80 % homology with a reference lipolytic enzyme of the *Humicola* family or the *Zygomycetes* family;
- 15 b) compared to said reference lipolytic enzyme comprises an amino acid alteration which is:
 - i) a substitution, deletion or insertion at a position corresponding to A20, Y21, G23, K24, N25, V63, R81, G82, R84, A257, W260, Y261, F262 or G266 in the *Humicola lanuginosa* DSM 4109 lipase;
 - 20 ii) a substitution of an amino acid corresponding to C268 or L269 in said lipase;
 - iii) a substitution corresponding to V60G, D62E, L93K, L97Q, K98E,F, E99D, P256A, G263E,Q,R,F,N, L264A,C,P,F,G,V,I, I265L,N,F or T267A,Q,P,S,V,E in said lipase;
 - 25 iv) an insertion corresponding to T267GS or T267GL in said lipase;
 - v) a peptide extension at the C-terminal which is A, P, MD, CP, AG, DG, AGG, PVGF, AGRF, PRGF, AGGF or AGGFS;
 - vi) a peptide extension at the C-terminal of 40-50 amino acids; or

- vii) a truncation of 1, 2, 3, 4, 5 or 6 amino acids at the C-terminal; and
- c) has an altered activity on an ester bond in a substrate compared with the reference lipolytic enzyme.
- 5 28. The lipolytic enzyme of claim 27 wherein the amino acid alteration corresponds to R84K,L,W, W260H,Q,C, G266A,C,D,N,L,I,S,T,P,V,F,W,E,K,R,Y or L269N,I,S.
29. The lipolytic enzyme of claim 27 or 28 which further comprises at least one further amino acid alteration which is a substitution, a deletion or an insertion corresponding to any of positions 22, 56-59, 61, 64, 83, 85, 91, 94, 249, 255 or 259
10 preferably S83T, G91A, N94D, D96S,W,F,G, Q249R or L259N,R,S,M,Q.
30. The lipolytic enzyme of any of claims 27-29 which further comprises a substitution corresponding to D62A,G,V, K98D, E99K, P256T, G263A and/or I265T,G,V.
31. The lipolytic enzyme of any of claims 27-30 which comprises a peptide extension at the N-terminal.
- 15 32. The lipolytic enzyme of any of claims 27-31 wherein the reference lipolytic enzyme is the lipase from *Humicola lanuginosa*.
33. The lipolytic enzyme of any of claims 27-31 wherein the reference lipolytic enzyme is the lipase from *Rhizomucor miehei*.
34. The lipolytic enzyme of any of claims 27-31 wherein the reference lipolytic enzyme is the lipase from *Fusarium oxysporum*.
20
35. A lipolytic enzyme which:
- a) is a polypeptide having an amino acid sequence which has at least 80 % homology with a reference enzyme which is the lysophospholipase from *Aspergillus foetidus*, the ferulic acid esterase from *Aspergillus niger*, the ferulic

acid esterase from *Aspergillus tubigensis* or phospholipase A1 from *Aspergillus oryzae*,

b) compared to said reference enzyme comprises an amino acid alteration which is a substitution, deletion or insertion at a position corresponding to 20-25, 56-64, 81-85, 91-98, 255-257 or 259-269 in the *Humicola lanuginosa* lipase, and

c) has an altered activity on an ester bond in a substrate compared with the reference enzyme.

36. The lipolytic enzyme of claim 35 wherein the alteration is at a position corresponding to Y21, E56, D57, V60, G61, D62, S83, R84, G91, L93, N94, D96, L97, K98, E99, P256, W260, Y261, G263, L264, I265, G266, T267 or L269 in the *Humicola lanuginosa* lipase

37. The lipolytic enzyme of claim 35 or 36 wherein the alteration is an extension or a truncation at the C-terminal, preferably by 1-5 amino acids.

38. The lipolytic enzyme of any of claims 27-37 wherein the altered activity is a lower activity towards a C₄-C₈ acyl bond in a triglyceride, or a lower ratio of activity towards a C₄-C₈ acyl bond in a triglyceride and a C₁₆-C₂₀ acyl bond in a triglyceride.

39. The lipolytic enzyme of claim 38 which comprises an amino acid alteration at a position corresponding to Y21, E56, D57, V60, G61, D62, R81, S83, R84, L259, Y261 or G266 in the *Humicola lanuginosa* lipase.

40. The lipolytic enzyme of any of claims 27-37 wherein the altered activity is a lower activity towards a C₁₆-C₂₀ acyl bond in a triglyceride, or a lower ratio of activity towards a C₁₆-C₂₀ acyl bond in a triglyceride and a C₄-C₈ acyl bond in a triglyceride.

41. The lipolytic enzyme of any of claims 27-37 wherein the altered activity is a higher phospholipase activity.

42. The lipolytic enzyme of claim 41 which comprises an amino acid alteration at a position corresponding to **R81**, R84, **S85**, G263, L264, 1265, G266, T267 or L269 in the *Humicola lanuginosa* lipase, preferably a substitution corresponding to G263A,E,Q,R; L264A,C,P,Q; I265L,N,T; G266A, C, D, N, L, I, S, T, P, V or T267A,Q or L269N.

43. The lipolytic enzyme of claims 41 or 42 which has a phospholipase activity greater than 0.1 nmol/min in a monolayer assay at pH 5 as described herein and/or a phospholipase activity greater than 100 PHLU/mg (preferably greater than 500 PHLU/mg) and/or a ratio of phospholipase activity to lipase activity greater than 0.1 PHLU/LU (preferably greater than 0.5 PHLU/LU).

44. The lipolytic enzyme of any of claims 41-43 wherein the parent lipolytic enzyme has a phospholipase activity below 50 PHLU/mg and/or a ratio of phospholipase activity to lipase activity below 0.1 PHLU/LU.

45. The lipolytic enzyme of any of claims 41-44 which comprises a **peptide** extension at the C-terminal, preferably comprising 1-5 amino acid residues, the first preferably being A, P or D, the second (if present) preferably being V, G or R, the third (if present) preferably being V, G or R, the fourth (if present) preferably being F, and the fifth (if present) preferably being S.

46. The lipolytic enzyme of any of claims **41-45** which comprises a deletion of amino acid residues at positions corresponding to positions C268 and L269 in the lipase of *Humicola lanuginosa* strain DSM 4109.

47. The lipolytic enzyme of any of claims 27-37 wherein the altered activity is a higher hydrolytic activity on a digalactosyl-diglyceride.

48. The lipolytic enzyme of claim 47 which comprises an amino acid alteration at a position corresponding to Y21, G23, N26, D57, 062, **R81**, S83, R84, **S85**, G266, T267 or L269 in the *Humicola lanuginosa* lipase, preferably comprising two or more

such alterations, most preferably further comprising at least one alteration in the lid region

49. The lipolytic enzyme of any of claims 27-48 which comprises an alteration in the lid which is a substitution of a negatively charged amino acid residue with a neutral or positively charged amino acid residue, or a substitution of a neutral amino acid residue with a positively charged amino residue.

50. The lipolytic enzyme of claim 49 which comprises an alteration in the lid at a position corresponding to position G91, D96 and/or E99 in the *Humicola lanuginosa* lipase, preferably a substitution which is G91A, D96S,W,F or E99K.

51. A lipolytic enzyme which is a variant of a parent lipase derived from *Humicola lanuginosa* strain DSM 4109 comprising the alterations E1 E,D,A+ G91G,A,S,T+ N94N,D+ D96D,G,F,W+ E99E,K+ G225G,R,K+ G263Q,N+ L264L,A,V+ I265I,T,S+ G266G,A,V,S,D,E+ T267T,A,V+ L269L,I,N,Q.

52. The lipolytic enzyme of claim 51 which further comprises SPIRR as a peptide extension at the N-terminal and/or AGGF or AGGFS as a peptide extension at the C-terminal.

53. A DNA sequence encoding the lipolytic enzyme of any of claims 27-52.

54. A vector comprising the DNA sequence of claim 53.

55. A transformed host cell harboring the DNA sequence of claim 53 or the vector of claim 54.

56. A method of producing the lipolytic enzyme of any of claims 27-52 comprising
a) cultivating the cell of claim 55 so as to express and preferably secrete the lipolytic enzyme, and
b) recovering the lipolytic enzyme.

57. A process for preparing a dough or a baked product prepared from the dough which comprises adding the lipolytic enzyme of any of claims 27-52 to the dough, wherein the lipolytic enzyme preferably has phospholipase and/or digalactosyl diglyceride activity.

5 58. The process of claim 57 which further comprises adding to the dough an endo-amylase and/or a phospholipid.

59. The process of claim 57 or 58 wherein the endo-amylase is from *Bacillus*, and is preferably a maltogenic amylase from *B. stearothermophilus*,

10 60. A process for reducing the content of phospholipid in an edible oil, comprising treating the oil with the lipolytic enzyme of any of claims 41-46, 51 or 52 so as to hydrolyze a major part of the phospholipid, and separating an aqueous phase containing the hydrolyzed phospholipid from the oil.

15 61. A process for improving the filterability of an aqueous solution or slurry of carbohydrate origin which contains phospholipid, which process comprises treating the solution or slurry with the lipolytic enzyme of any of claims 41-46, 51 or 52, wherein the solution or slurry preferably contains a starch hydrolysate, particularly a wheat starch hydrolysate.

20 62. A detergent composition comprising a surfactant and the lipolytic enzyme of any of claims 27-52, wherein the lipolytic enzyme preferably has a specificity for long-chain fatty acids corresponding to a ratio of SLU to LU above 3.

25 63. A method of enhancing the flavor of a food product containing milk fat, comprising treating the food product with the lipolytic enzyme of any of claims 27-52 so as to release free fatty acids, wherein the lipolytic enzyme preferably has a specificity for short-chain fatty acids corresponding to a ratio of SLU to LU below 0.5, more preferably below 0.2, e.g. below 0.7.

64. A method of preparing a dough or a baked product prepared from the dough, comprising:

- 5 a) testing at least one lipolytic enzyme for its hydrolytic activity towards a C₄-C₈ acyl bond in a triglyceride, a C₁₅-C₂₀ acyl bond in a triglyceride, digalactosyl diglyceride and a phospholipid,
 - b) selecting a lipolytic enzyme having hydrolytic activity towards digalactosyl diglyceride and the phospholipid, and having a ratio of activity towards the C₁₅-C₂₀ acyl bond and the C₄-C₈ acyl bond which corresponds to a SLU/LU ratio of at least 3, and
 - 10 c) adding the selected lipolytic enzyme to the dough.
-

1/1

	1				50
rhimi	SIDGGIRAAT	SQEINELTYT	TTLSANSYCR	TVIPGA...T	WDC..IHCD
rhidl	SDGGKVVAAT	TAQIQEFTKY	AGIAATAYCR	SVVPGN...K	WDC..VQCQK
SP400	-----EVS	QDLFNQFNLF	AQYSAAAYCG	KNNDAPAGTN	ITCTGNACPE
Pcl	-----DVS	TSELDQFEFW	VQYAAASYVE	ADYTAQVGDK	LSCSKGNCPE
FoLnp11	-----AVGVT	TTDFSNEKFY	IQHGAAAYC.	.NSEAAAGSK	ITCSNNGCPT
	51				100
rhimi	TE..DLKIIK	TWS.TLIYDT	NAMVARGDSE	KTIYIVFRGS	SSIRNWIADL
rhidl	WV.PDGKIIT	TFT.SLLSDT	NGYVLRSDKQ	KTIYLVFRGT	NSFRSAITDI
SP400	VEKADATFLY	SFEDSGVGDV	TGFLALDNTN	KLIVLSFRGS	RSIENWIGNL
Pcl	VEATGATVSY	DFSDSTITDT	AGYIAVDHTN	SAVVLAFRGS	YSVRNWWADA
FoLnp11	VQNGATIVT	SFVG.SKTGI	GGYVATDSAR	KEIWSFRGS	INIRNWLTNL
	101				150
rhimi	TFVPVSY.PP	VSGTKVHKGF	LDSYGEVQNE	LVATVLDQFK	QYPSYKVAVT
rhidl	VFNFSKY.KP	VKGAKVHAGF	LSSYEQWND	YFPWQEQLT	AHPTYKVIVT.
SP400	NFDLKEINDI	CSGCRGHDGF	TSSWRSVADT	LRQKVEDAVR	EHPDYRWFT
Pcl	TFVHTNP.GL	CDGCLAELGF	WSSWKLVRDD	IIKELKEWA	QNPNYELWV
FoLnp11	DFGQEDC.SL	VSGCGVHSGF	QRAWNEISSQ	ATAAVASARK	ANPSFNVIST
	151				200
rhimi	GHS LGGATAL	LCALDLYQRE	EGLSSSNLFL	YTQGQPRVGD	PAFANYWST
rhidl	GHS LGGAQAL	LAGMDLYQRE	PRLSPKNLSI	FTVGGPRVGN	PTFAYYVEST
SP400	GHS LGGALAT	VAGADLRGN.	.GY...DIDV	FSYGAPRVGN	RAFAEFLTVQ
Pcl	GHS LGAAVAT	LAATDLRGK.	.GYP..SAKL	YAYASPRVGN	AALAKYITAQ
FoLnp11	GHS LGGAVAV	LAAANLRVG.	.GT...PVDI	YTYGSPRVGN	AQLSAFVSNQ
	201				250
rhimi	G.IPYRRTVN	ERDIVPHLPP	AAFGLHAGE	EYWITD.NSP	...ETVQ
rhidl	G.IPFQRTVH	KRDIVPHVPP	QSEGLHPGV	ESWIKS.GT.	...SNVQ
SP400	TGGTLYRITH	TNDIVPRLPP	REFGYSHSSP	EYWIKS.GTL	V.PVTRNDIV
Pcl	G..NNFRFTH	TNDPVPKLPL	LSMGYVHVSP	EYWITS.PNN	A.TVSTSDIK
FoLnp11	A.GGEYRVTH	ADDPVPRLPP	LIFGYRHPTP	EEWLSGGGGD	KVDYTISDVK
	251				300
rhimi	VCTSDLETS	CSNSIVPFT.	.SVLDHLSYF	GINTGLCT--	-----
rhidl	ICTSEIETKD	CSNSIVPFT.	.SILDHLSYF	DINEGSCL--	-----
SP400	KIEGID.ATG	GNNQP.NIP.	.DIPAH LWYF	.GLIGTCL--	-----
Pcl	VIDGDV.SFD	GNTGTGLPLL	TDPEAHIWYF	.VQVDAGKGP	GLPFKRV---
FoLnp11	VCEGAA.NLG	CNGGT.LGL.	.DIAAHLHYF	.QATDACNAG	GFSWRRYRSA
	301				338
rhimi	-----	-----	-----	-----	-----
rhidl	-----	-----	-----	-e_m--	...
SP400	-----	-----	-----	-----	...
Pcl	-----	-----	-----	-----	...
FoLnp11	ESVDKTRATMT	DAELEKKLNS	YVQMDKEYVK	NNQARS..	...

Fig. 1

Alignment of lipase sequences

SEQUENCE LISTING

<110> Novo Nordisk A/S

<120> Lipolytic enzyme variants

<130> 5559

<140>

<141>

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 4244

<400> 1

tcaagaatag ttcaacaag aaga

24

<210> 2

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Description of
Artificial Sequence :AP

<400> 2

ggttgtetaa ctcttcctt ttcg

24

<210> 3

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: FOL14

<400> 3

tgtcccygmgw ctccckcck

19

<210> 4

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: FOL15

<400> 4

gaagtamyry agrtgmgcag sratatc

27

<210> 5

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: FOL16

<400> 5

gatatysctg ckayctryr ktacttc

27

<210> 6

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: H7

<400> 6

cggaatgtta ggctgggttat tgc

23

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: KBoj14

<400> 7

cttttcggtt agagcggatg

20

<210> 8

<211> 120

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:KBoj32

<220>

<221> misc_feature

<222> (58)

<223> 1: A 90, C 10

<220>

<221> misc_feature

<222> (59)..(60)

<223> 2: G 3,A 91,T 3,C 3

<220>

<221> misc_feature

<222> (61)

<223> 3: A 25, T 75

<220>

<221> misc_feature

<222> (62)

<223> 4: G 2, A 4, T 5, C 89

<220>

<221> misc_feature

<222> (63)

<223> 5: G 2, A 13, T 4, C 81

<220>

<221> mix-feature

<222> (64)

<223> 3: A 25, T 75

<220>

<221> misc_feature

<222> (65)

<223> 4: G 2, A 4, T 5, C 89

<220>

<221> mix-feature
<222> (66)
<223> 5: G 2, A 13, T 4, C 81

<220>
<221> misc_feature
<222> (68)
<223> 6: G 91, A 3, T 3, C 3

<220>
<221> misc_feature
<222> (69)
<223> 7: G 48, A 2, T 2, C 48

<220>
<221> misc_feature
<222> (71)
<223> 8: A 92, T8

<220>
<221> misc_feature
<222> (73)
<223> 9: A 97, T 3

<220>
<221> mix-feature
<222> (74)
<223> 10: G 1, A 1, T 1, C 97

<220>
<221> misc_feature
<222> (75)
<223> 11: G 1, A 97, T 1, C 1

<220>
<221> misc_feature
<222> (77)
<223> 12: G 94, A 2, T 2, C 2

<220>
<221> misc_feature
<222> (78)
<223> 13: G 1, A 1, T 91, C 7

<220>
<221> misc_feature
<222> (79)
<223> 1: A 90, C 10

<220>
<221> misc_feature
<222> (80)
<223> 14: G 1, A 1, T 7, C 91

<220>
<221> misc_feature
<222> (81)
<223> 15: G 2, A 2, T 2, C 94

<220>
<221> misc_feature
<222> (82)
<223> 16: A 80, T 20

<220>
<221> misc_feature
<222> (83)
<223> 17: G 6, A 90, T 2, C 2

<220>
<221> misc_feature
<222> (84)
<223> 18: G 2, A 2, T 94, C 2

<220>
<221> misc_feature
<222> (86)
<223> 19: G 5, A 91, T 4

<220>
<221> misc_feature
<222> (87)
<223> 20: G 96, C4

<220>
<221> misc_feature
<222> (89)
<223> 21: G 4, T 5, C 91

<220>
<221> mix-feature
<222> (90)
<223> 22: G 4, C 96

<220>
<221> mix-feature

<222> (111)

<223> 23: G 94, C 3, T 3

<400> 8

gtaagcgtga	cataactaat	tacatcatgc	ggccctctag	agtcgaccca	gccgctannn	60
nnnnnnsnnc	nannnsnnnn	nnnntnncnn	gaagtacat	aggtgcgcag	ngatatccgg	120

<210> 9

<211> 117

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:KBoj33

<220>

<221> misc_feature

<222> (68)

<223> 8: A 92, T8

<220>

<221> misc_feature

<222> (70)

<223> 9: A 97, T 3

<220>

<221> misc_feature

<222> (71)

<223> 10: G 1, A 1, T 1, C 97

<220>

<221> misc_feature

<222> (72)

<223> 11: G 1, A 97, T 1, C 1

<220>

<221> misc_feature

<222> (74)

<223> 12: G 94, A 2, T 2, C 2

<220>

<221> misc_feature

<222> (75)

<223> 13: G 1, A 1, T 91, C 7

<220>

<221> misc feature

<222> (76)

<223> 1: A 90, C 10

<220>

<221> misc_feature

<222> (77)

<223> 14: G 1, A 1, T 7, C 91

<220>

<221> misc_feature

<222> (78)

<223> 15: G 2, A 2, T 2, C 94

<220>

<221> misc_feature

<222> (79)

<223> 16: A 80, T 20

<220>

<221> misc_feature

<222> (80)

<223> 17: G 6, A 90, T 2, C 2

<220>

<221> misc_feature

<222> (81)

<223> 18: G 2, A 2, T 94, C 2

<220>

<221> nix-feature

<222> (83)

<223> 19: G 5, A 91, T 4

<220>

<221> misc_feature

<222> (84)

<223> 20: G 96, C4

<220>

<221> misc_feature

<222> (86)

<223> 21: G 4, T 5, C 91

<220>

<221> misc_feature

<222> (87)

<223> 22: G 4, C 96

<220>

<221> misc_feature

<222> (108)

<223> 23: G 94, C 3, T 3

<400> 9

gtaagcgtga	cataactaat	tacatcatgc	ggccctctag	agtcgaccca	gccgcgccgc	60
gcactacnan	nnsnnnnnnn	ntnncnngaa	gtaccatagg	tgccgagnga	tatccgg	117

<210> 10

<211> 120

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:KBoj34

<220>

<221> mix-feature

<222> (58)

<223> 1: A 90, C 10

<220>

<221> misc_feature

<222> (59)..(60)

<223> 2: G 3,A 91,T 3,C 3

<220>

<221> misc_feature

<222> (61)

<223> 3: A 25, T 75

<220>

<221> misc_feature

<222> (62)

<223> 4: G 2, A 4, T 5, C 89

<220>

<221> misc_feature

<222> (63)

<223> 5: G 2, A 13, T 4, C 81

<220>

<221> mix-feature

<222> (64)

<223> 3: A 25, T 75

--
<220>
<221> misc_feature
<222> (65)
<223> 4: G 2, A 4, T 5, C 89

<220>
<221> misc_feature
<222> (66)
<223> 5: G 2, A 13, T 4, C 81

<220>
<221> misc_feature
<222> (68)
<223> 6: G 91, A 3, T 3, C 3

<220>
<221> misc_feature
<222> (69)
<223> 7: G 48, A 2, T 2, C 48

<220>
<221> misc_feature
<222> (70)
<223> 20: G 96, C4

<220>
<221> misc_feature
<222> (71) ..(72)
<223> 18: G 2, A 2, T 94, C 2

<220>
<221> misc_feature
<222> (73)
<223> 9: A 97, T 3

<220>
<221> misc_feature
<222> (74)
<223> 10: G 1, A 1, T 1, C 97

<220>
<221> misc_feature
<222> (75)
<223> 11: G 1, A 97, T 1, C 1

--
<220>
<221> misc_feature
<222> (77)

<223> 12: G 94, A 2, T 2, C 2

<220>

<221> misc_feature

<222> (78)

<223> 13: G 1, A 1, T 91, C 7

<220>

<221> misc_feature

<222> (79)

<223> 1: A 90, C 10

<220>

<221> misc_feature

<222> (80)

<223> 14: G 1, A 1, T 7, C 91

<220>

<221> misc_feature

<222> (81)

<223> 15: G 2, A 2, T 2, C 94

<220>

<221> misc_feature

<222> (82)

<223> 16: A 80, T 20

<220>

<221> misc_feature

<222> (83)

<223> 17: G 6, A 90, T 2, C 2

<220>

<221> misc_feature

<222> (84)

<223> 18: G 2, A 2, T 94, C 2

<220>

<221> misc_feature

<222> (86)

<223> 19: G 5, A 91, T 4

<220>

<221> misc_feature

<222> (87)

<223> 20: G 96, C4

<220>

<221> mix-feature

<222> (89)

<223> 21: G 4, T 5, C 91

<220>

<221> misc_feature

<222> (90)

<223> 22: G 4, C 96

<220>

<221> misc_feature

<222> (111)

<223> 23: G 94, C 3, T 3

<400> 10

gtaagcgtga	cataactaat	tacatcatgc	ggccctctag	agtcgaccca	gccgctannn	60
nnnnnnsnnn	nnnnnsnnnn	nnnnnnncnn	gaagtaccat	aggtgcgcag	ngatatccgg	120

<210> 11

<211> 82

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:KBoj36

<400> 11

gtaagcgtga	cataactaat	tacatcatgc	ggccctctag	agtcgaccca	gccgctagtt	60
acaggcgtca	gtcgcttgga	ag				82

<210> 12

<211> 82

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:KBoj37

<400> 12

gtaagcgtga	cataactaat	tacatcatgc	ggccctctag	agtcgaccca	gccgctaagc	60
gttacaggcg	tcagtcgcct	gg				82

<210> 13

<211> 82

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:KBoj38

<400> 13

gtaagcgtga	cataactaat	tacatcatgc	ggccctctag	agtcgaccca	gccgctaacc	60
agcgttacag	gcgtcagtcg	cc				82

<210> 14

<211> 82

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:KBoj39

<400> 14

gtaagcgtga	cataactaat	tacatcatgc	ggccctctag	agtcgaccca	gccgctagcc	60
accagcgtta	caggcgtcag	tc				82

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 99/00664

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12N 9/20 // C11D 3/28⁵ A21D 8/04 A23L 1/105
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Oils-fats-lipids 1995. Proceedings of the World congress of International society for fat research, 21st. Oct. 1995, Vol. 1, Atomi H. et al: "Microbial Lipases-from Screening to Design", page 48 - page 51 --	1,6-17,21, 25-34,38-50, 53-63
X	Protein Science, Volume 8, 1999, Holger Scheib et al, "Stereoselectivity of Mucorales lipases toward triacylglycerols- A simple solution to a complex problem", page 215 - page 221, see abstract, page 217 --	1,6-17,21, 25-34,38-50, 53-63
X	WO 9205249 A1 (NOVO NORDISK A/S), 2 April 1992 (02.04.92), see abstract, page 2, lines 7-20, page 3, lines 12-14, lines 25-30, page 4, lines 1-18 --	1,6-17,21, 25-34,38-50, 53-63

☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

Special categories of cited documents:

- 'A' document defining the general state of the art which is not considered to be of particular relevance
'E' earlier document but published on or after the international filing date
'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
'O' document referring to an oral disclosure, "see. exhibition or other means
'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance: the claimed invention cannot be considered novel a cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

'&' document member of the same patent family

Date of the actual completion of the international search

8 May 2000

Date of mailing of the international search report

09 -05- 2000

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. + 46 8 666 02 86

Authorized officer

Yvonne Stösteen/EÖ
Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK

99/00664

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9401541 A1 (NOVO NORDISK A/S), 20 January 1994 (20.01.94), see abstract, page 2, lines 19-24, page 5, lines 29-32 --	1,6-17,21, 25-34,38-50, 53-63
A	Croatica Chemica Acta, Volume 68, No 3, 1995, Peter Stadler et al, "Understanding Lipase Action and Selectivity. Conference Paper" page 649 - page 674 --	1,6-17,21, 25-34,38-50, 53-63
A	Jaocs, Volume 75, No 6, 1998, Mohamed M. Soumanou et al, "Two-Step Enzymatic Reaction for the synthesis of Pure Structured Triacylglycerides" page 703 - page 710 --	1,6-17,21, 25-34,38-50, 53-63
A	ISSN 1392-0146 Biologija. 1995. Nr. 1-2, I. Bachmatova et al: "Lipase of Pseudomonas mendocina 3121-1 and its Substrate Specificity", page 57 - page 58 -- -----	1,6-17,21, 25-34,38-50, 53-63

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 99/00664Box I Observations where certain claims were found **unsearchable** (Continuation of item I of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).:

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

~~This~~ International Searching Authority found multiple inventions in this international application, as follows:

see next sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claim 1, part of 25-34, part of 38-50 and part of 55-63

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

The international Searching Authority considers that the present application contains at least seven inventions.

The observation is based on the following reasons:

The inventions listed do not relate to a single inventive concept under PCT Rule 13.1 because they lack the same or corresponding special technical feature for the following reasons:

What could be seen as a unifying feature of the claims is a method for producing lipase variants with altered activity on ester bonds of the substrate.

The prior art discloses methods for producing lipase variants with altered substrate specificity on ester bonds of the substrate. These methods are based on the knowledge of the 3-dimensional structure of lipase. See e.g. Atomi et al, Oils-Fats-Lipids 1995, Proc. World Congr.Int Soc. Fat Res., 2nd, 1996, Meeting Date 1995, Volume 1, 49-50, which discloses mutated lipases with altered specificity towards long and short chain fatty acid Me esters. It is also known from many patent documents to make lipase variants with altered catalytic activity -see e.g. WO 92105249 and WO 94/01541.

Unity of invention exists only when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding "special technical feature"- i.e. features that define a contribution which each of the inventions make over prior art. (See Annex B to administrative Instructions and Rule 13.1)

Therefore the technical feature being a method of producing lipase variants with altered activity on the ester bond of the substrate is not a feature that define a contribution over prior art.

Consequently, the different methods of producing lipase variants cannot be seen as a unifying novel special technical feature.

The claims consist of at least the following six inventions:

- 1) A method of producing a lipolytic enzyme variant by altering an amino acid within 10Å of the C atom at the sn2 position of the glycerol part of a substrate triglyceride in a three-dimensional structure of the parent lipolytic enzyme and substrate. See claim 1. The first invention claimed also relates to lipolytic enzyme variants being mutated in the region defined in claim 1 and having an altered activity on the selected ester bond. See claim 2 1 and part of the following claims; claims 6-17,25-34,38-50 and 53-63.
- 2) A method of producing a lipolytic enzyme variant by altering an amino acid in the catalytic triad of the parent enzyme. See claim 2.
- 3) A method of producing a lipolytic enzyme variant by altering an amino acid situated at the C-terminal of an active His residue. See claim 3.
- 4) A method of producing a lipolytic enzyme variant by altering an amino acid among 10 amino acid residues at the C-terminal. See claim 4.
- 5) A method of producing a lipolytic enzyme variant by altering an amino acid in the lid. See claim 5.
- 6) A method of preparing a lipolytic enzyme variant for use in baking, characterized by screening for enzyme variants having a) a higher ratio selectivity for long-chain fatty acyl groups, b) a higher activity on digalactosyl diglyceride and a higher phospholipase activity. See claims 18-20.

Since, however claims 2 -3 and claims 4-5 could be treated for one extra fee for each pair of invention, the applicant is only invited to pay for three extra fees in total.

Therefore, although the claims are composed of at least six different inventions, the applicant is invited to pay only three extra fee as the rest of the claims could be searched without effort justifying six additional fees.

Due to the very complex construction of the claims and the fact that the search so far has not covered all aspects of the invention, it may be that further non-unity remarks can appear.

The search has been restricted to the first invention.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 99/00664

Several of the claims are constructed in such a complex way and being so broad and speculative that it is not possible to carry out a meaningful complete search. See Art 17(2) (a). Some examples of such claims are:

Claims 7-8 and 27-34 which are too broadly formulated and relates to a large number of variable positions in the amino acid chain without being linked to one of the specific regions of claims 1-4. **Therefore** it will not be possible to perform a meaningful search for the whole scope of these claims.

Claims 10, 14, 15 and 17 which represent some of the multiple dependent claims of the application being too unclear because they are linked to any of the specific region of claims 1-5. It will not be considered possible to permit a meaningful search for the whole scope of the claims. See Rule 6.4(a).

Claims 35-50 which relate to lipolytic enzymes where the sites for alterations are specified as the positions corresponding to specific positions in the *Humicola lanuginosa* lipase are too indefinite to be searched for.

Patent claims taken singly as well as in totality, must be clear and concise (PCT Article 6) in order to enable potential users to ascertain, **without undue burden**, the scope of the protection.

The search of the first invention has been restricted to a method of producing lipase variants where amino acids have been altered in the region specified in claim one. The search also covers lipase variants produced by the method of claim one.

INTERNATIONAL SEARCH REPORT
Information on patent family members

02/12/99

International application No.

PCT/DK 99/00664

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9205249 A1	02/04/92	AT 169671 T AU 657278 B AU 8617291 A CA 2092615 A DE 69129988 D,T DK 219490 D EP 0548228 A,B SE 0548228 T3 ES 2121786 T FI 931124 A JP 6501153 T US 5869438 A US 5892013 A DK 219590 D DK 219690 D	15/08/98 09/03/95 15/04/92 14/03/92 18/03/99 00/00/00 30/06/93 16/12/98 12/05/93 10/02/94 09/02/99 06/04/99 00/00/00 00/00/00
WO 9401541 A1	20/01/94	BR 9306694 A EP 0652945 A JP 7508416 T MX 9304027 A	08/12/98 17/05/95 21/09/95 31/05/94